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Acinetobacter spp. are nosocomial pathogens, commonly associated with 
opportunistic infections such as pneumonia, urinary tract and skin and soft tissue 
infections, particularly in intensive care units and in military casualties returning from 
Iraq and Afghanistan. Their propensity to acquire resistance determinants and over-
express existing resistance genes allows them to avoid eradication by antibiotics and 
biocides. A common cause of multidrug resistance is innate and over-production of 
efflux pumps. This study aimed to establish a method to distinguish between isolates 
that demonstrate different levels of efflux and to apply the method to study defined 
efflux pump mutants. MICs of a range of antibiotics were determined against clinical 
isolates representative of resistant and susceptible isolates commonly found causing 
infection in Singapore hospitals and specific pump deletion mutants. A Hoechst 
33342 accumulation assay was developed and used to compare efflux in the clinical 
isolates and pump deletion mutants and data were compared with those from 
ethidium bromide and norfloxacin accumulation assays. Measurement of 
accumulation of H33342, with supporting ethidium bromide accumulation data, 
showed a significant difference in the efflux activity of specific pump deletion mutants 
compared with the parental strain. Data obtained in this study support previous work 
carried out with other strains and isolates of A. baumannii and provide an insight into 
the contribution of RND systems AdeFGH and AdeIJK to MDR in clinical isolates 
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Chapter 1. Introduction 
1.1. Acinetobacter species 
Acinetobacter are a Gram negative coccobacilli responsible for an increasing number 
of nosocomial infections in the UK and worldwide. Acinetobacter are currently 
defined as aerobic, non-fermenting, non-fastidious, non-motile, catalase positive and 
oxidase negative, with a DNA G+C content of 38% to 50% (Rossau, Van Landschoot 
et al. 1991). Acinetobacter are opportunistic pathogens and are a rising problem in 
immunocompromised patients within the hospital setting. The clinical success of this 
organism is down to a number of factors including its propensity to acquire antibiotic 
resistance determinants and to over-express existing intrinsic resistance genes, 
allowing it to avoid eradication by antibiotics and biocides. Its ability to survive 
desiccation means it is also able to persist in the hospital environment for extended 
periods of time (Wendt, Dietze et al. 1997; Jawad, Seifert et al. 1998). 
The taxonomy of Acinetobacter has a long and complicated background and there 
are still difficulties with species identification. The bacterium was first identified in 
1911 by the Dutch microbiologist, Beijerinck, who isolated a bacterium he named 
Micrococcus calcoaceticus from soil samples (Beijerink 1911). Since then, bacteria 
now known as Acinetobacter have been isolated many times and assigned to various 
genera. In 1971, the genus Acinetobacter was officially acknowledged by the 
Subcommittee on Nomenclature of Moraxella and Allied Bacteria (Lessel 1971). In 
1986, the genera was divided into 12 DNA groups with formal species names 
(Bouvet and Grimont 1987) and over the past 26 years has been further categorised 
to give at least 33 individual genomic groups, 20 with formal species names (Table 
1.1.) (Towner 2009).  
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Not all Acinetobacter species pose a threat to human health. Many species are non-
pathogenic and can be isolated from the soil and often form part of the normal human 
skin flora (Baumann 1968; Seifert, Dijkshoorn et al. 1997). This has led to the 
common misconception that all Acinetobacter species are ubiquitous and that 
pathogenic species such as A. baumannii can be isolated from environmental 
sources. However, it is now generally accepted that this is not the case. Although 
Acinetobacter can be isolated from human skin, highly pathogenic species such as A. 
baumannii are rarely found colonising the skin of healthy humans (Berlau, Aucken et 
al. 1999). Clinically relevant strains of Acinetobacter are often found colonising 
hospital surfaces, hospital staff and medical instrumentation, although the natural 
habitat of these strains remains unknown. 
1.1.1. Acinetobacter baumannii - calcoaceticus complex 
Four of the identified Acinetobacter species are often grouped into the Acinetobacter 
calcoaceticus – baumannii (Acb) complex. This group comprises of A. baumannii, A. 
calcoaceticus, A. genomospecies (gsp) 3 and A. gsp 13 (recently renamed as A. pittii 
and A. nosocomialis respectively) (Gerner-Smidt 1992; Nemec, Krizova et al. 2011). 
A. baumanni, A. pittii and A. nosocomialis are clinically relevant species, often 
implicated in infection, whereas A. calcoaceticus is largely non-pathogenic and is 
rarely identified in the hospital setting (Peleg, Seifert et al. 2008; Koh, Tan et al. 
2011). Therefore, from a clinical perspective, identification of different species of 
Acinetobacter, especially those within the Acb complex, is extremely important. 
Species also has implications for treatment and infection control as many of the non-
A. baumannii complex species are drug susceptible and infection control is not 
necessary (Chuang, Sheng et al. 2011). However, discrimination between species is 
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difficult, particularly between members of the A. baummanii complex, which cannot 
be differentiated phenotypically and are often misidentified (Gerner-Smidt, Tjernberg 
et al. 1991; Gerner-Smidt 1992). Semi-automated systems such as the API 20NE 
system are often unreliable and also cannot distinguish between closely related 
species (Bernards, van der Toorn et al. 1996). There are a number of methods 
currently used for the routine identification of Acinetobacter species in clinical 
laboratories; DNA-DNA hybridisation is the reference standard (Bouvet and Grimont 
1986). However this process is lengthy and is impractical for a routine diagnostic 
laboratory. For this reason various methods have been adopted and verified for 
species identification. These include 16S rRNA gene restriction (ARDRA) 
(Vaneechoutte, Dijkshoorn et al. 1995), high resolution fingerprint analysis by 
amplified fragment length polymorphism (AFLP) (Janssen, Maquelin et al. 1997), 
ribotyping (Gerner-Smidt 1992),  tRNA spacer analysis (Ehrenstein, Bernards et al. 
1996), restriction analysis of 16S-23S rRNA intergenic spacer regions (Dolzani, Tonin 
et al. 1995; Chang, Wei et al. 2005) and sequence analysis of the rpoB gene (La 
Scola, Gundi et al. 2006). Nonetheless, apart from a small number of Acinetobacter 
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various regions in a country and can even spread worldwide (van Dessel, Dijkshoorn 
et al. 2004; Coelho, Turton et al. 2006). A. baumannii European (EU) clones I and II 
were first identified as outbreak strains in North-western Europe in 1996 (Dijkshoorn, 
Aucken et al. 1996). A third clone was later identified as a European outbreak strain 
and named EU clone III (van Dessel, Dijkshoorn et al. 2004). These clones are 
widespread throughout Europe and contribute significantly to the spread of 
carbapenem-resistant Acinetobacter (Towner, Levi et al. 2008). Other individual 
lineages are more prevalent in certain areas of Europe, such as the AYE-VEB-1 
clone found in France and Belgium (Naas, Bogaerts et al. 2006)  and the OXA-40 
(OXA-24) carbapenem resistant clone found in Spain and Portugal (Da Silva, 
Quinteira et al. 2004). The EU clones are in fact international lineages and not limited 
to Europe. Outbreaks have been identified in the USA and South Africa (van Dessel, 
Dijkshoorn et al. 2004; Petersen, Cannegieter et al. 2011). In Asia, carbapenem 
resistant European clones have been described in hospitals in China (Fu, Zhou et al. 
2010) and Korea (Park, Lee et al. 2010). In Singapore, carbapenem resistance is 
also observed in clinical isolates, with outbreak isolates related to EU clones I and II 
identified in the hospital setting, and the majority of carbapenem resistance due to 
OXA-23 carrying clones (Park, Lee et al. 2010). In a study of UK hospitals between 
2003 and 2006, sub-lineages of EU clone II dominated, with the South-east (SE) and 
OXA-23 clones being the most prevalent (Coelho, Turton et al. 2006).  
 
1.2. Acinetobacter Infection 
1.2.1. Hospital Acquired Infection 
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Acinetobacter species most commonly cause nosocomial infections, including 
ventilator-associated pneumonia, skin and soft-tissue infections, wound infections, 
surgical site infections, catheter-related and urinary tract infections, secondary 
meningitis and bloodstream infections (Forster and Daschner 1998). Studies have 
found that up to 18% of patients infected with A. baumannii develop bacteraemia, 
most often acquired in the intensive care unit (ICU) (Cisneros, Reyes et al. 1996). 
The assessment of the outcome of Acinetobacter infection is difficult and reported 
mortality rates range from 5% in general wards to 54% in the ICU (Poutanen, Louie 
et al. 1997; Siau, Yuen et al. 1999). Seifert et al. showed the crude mortality rate of 
A. baumannii bacteraemia to be as high as 44%. However, it is difficult to determine 
morbidity and mortality directly attributable to Acinetobacter as opposed to co-
morbidity, which is very common in these patients. Death attributable to A. baumannii 
bacteraemia, at 19%,  was assessed to be much lower than the crude mortality rate 
(Seifert, Strate et al. 1995). Several predisposing factors to infections with 
Acinetobacter have been identified. These include immunosuppression, unscheduled 
hospital admission, respiratory failure at admission, previous antimicrobial therapy, 
previous sepsis in ICU and invasive procedures; all of which have been recognised 
as risk factors for Acinetobacter infection (Garcia-Garmendia, Ortiz-Leyba et al. 
2001). Acinetobacter can be cultured from different environmental sites within 
hospitals and it is thought that cross contamination between sites is a major mode of 
transmission in hospital outbreaks (van den Broek, Arends et al. 2006). Carriage of 
Acinetobacter on the hands of hospital staff and on medical instrumentation can 
contribute to the spread of the organism. The ability of certain Acinetobacter species 
to survive on dry surfaces for extended periods of time may also increase 
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transmissibility. It has been suggested that desiccation tolerance, along with 
multidrug resistance demonstrated by some strains, may explain why Acinetobacter 
is able to establish itself in the hospital environment and cause recurring nosocomial 
outbreaks (Jawad, Seifert et al. 1998). 
1.2.2. Community Acquired Infection 
Although most common in the hospital environment, community acquired 
Acinetobacter infection has been observed. Recently in Portugal, necrotising 
community acquired pneumonia due to Acinetobacter lwoffii contamination of a 
nebuliser in a previously healthy child was identified (Moreira Silva, Morais et al. 
2011). This type of infection is usually associated with underlying conditions such as 
alcoholism, smoking, chronic obstructive pulmonary disease and diabetes mellitus 
and is a particular problem in tropical climates such as Southeast Asia and Australia, 
where skin carriage is more common due to environmental conditions (Anstey, Currie 
et al. 1992; Chu, Leung et al. 1999). In these areas A. baumannii can be a cause of 
severe community-acquired pneumonia, especially in young alcoholic patients (Chen, 
Hsueh et al. 2001). 
1.2.3. Infection in Military and Disaster Zone Casualties 
Acinetobacter species are also commonly isolated from deep wound and burn 
infections, and osteomyelitis in military and disaster zones. Reports from the 
Marmara earthquake in Turkey in 1999 described a high incidence of Acinetobacter 
strains as responsible for healthcare associated infection in trauma patients (Oncul, 
Keskin et al. 2002).  Acinetobacter wound infections have been reported in military 
casualties returning from Iraq and Afghanistan, many of them exhibiting MDR 
(Murray, Roop et al. 2006; Johnson, Burns et al. 2007; Petersen, Riddle et al. 2007; 
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Scott, Deye et al. 2007). Due to the misconception that A. baumannii is ubiquitous 
and can be isolated from environmental sources it was initially considered that the 
organism was being introduced at the site of injury, or was due to skin colonisation at 
the time of injury. However, there is now evidence of the role of environmental 
contamination and transmission of organisms within health care facilities and it is 
likely that patients with a prolonged stay in US field hospitals provide a reservoir for 
this organism (Davis, Moran et al. 2005; Scott, Deye et al. 2007). 
 
1.3. Treatment of Acinetobacter Infections 
Due to the wide spectrum of intrinsic and acquired antibiotic resistance mechanisms 
present in this pathogen, treatment of Acinetobacter infections poses a major 
challenge. Clinical isolates displaying resistance to a number of classes of antibiotics 
are commonly observed and treatment of MDR isolates is now limited to a small 
number of antibiotics: 
- Sulbactam is a β-lactamase inhibitor that binds penicillin binding protein 
(PBP) protein 2 (Urban, Go et al. 1995). Whilst its primary purpose is to limit 
the degradation of active β-lactams by β-lactamases, it also demonstrates 
intrinsic activity against Acinetobacter species when used alone (Levin 2002; 
Higgins, Wisplinghoff et al. 2004). However, sulbactam is most commonly 
used in combination with other antibiotics and an ampicillin-sulbactam 
combination provides an effective therapeutic option for the treatment of MDR 
Acinetobacter infections (Levin, Levy et al. 2003). Oliveira et al. showed that 
ampicillin-sulbactam may be more efficacious in treating carbapenem-resistant 
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Acinetobacter spp. than polymyxins (Oliveira, Prado et al. 2008) and it has 
been suggested that sulbactam should be the preferred treatment for 
infections with this pathogen (Levin 2002; Peleg 2007). Unfortunately, 
increasing clinical use has led to a rise in sulbactam resistance and minimum 
inhibitory concentrations (MICs) of >32 µg/ml have been observed in clinical 
isolates (Henwood, Gatward et al. 2002; Higgins, Wisplinghoff et al. 2004). 
Resistance to an ampicillin-sulbactam combination has also been seen; in a 
study conducted in Taiwan, 70% of clinical isolates were ampicillin-sulbactam 
resistant (Yang, Chang et al. 2010). 
- Polymyxins are polycationic lipopeptide antimicrobials that show bactericidal 
activity against Acinetobacter spp. They include polymyxin B, polymyxin E and 
colistin. The polymyxins were discovered as chemotherapeutic agents in 1947 
(Stansly, Shepherd et al. 1947), but use has been minimal due to concerns 
over neurotoxicity and nephrotoxicity (Falagas, Fragoulis et al. 2005; Falagas, 
Rafailidis et al. 2006). However, with MDR bacteria becoming more prevalent, 
the use of polymyxins has increased and in some cases is recommended for 
the treatment of carbapenem-resistant Acinetobacter (Kim, Peleg et al. 2009). 
Polymyxins show high success rates in the clinical setting. Kallel et al. showed 
a favourable outcome in 76% of patients treated with colistin in the ICU (Kallel, 
Bahloul et al. 2006) and others have shown success with polymyxin treatment 
against MDR Acinetobacter (Holloway, Rouphael et al. 2006; Falagas, 
Rafailidis et al. 2010). Resistance to these drugs is rare, although increasing 
use means that the isolation of resistant strains is on the rise (Matthaiou, 
Michalopoulos et al. 2008) with reported resistance levels of up to 18% in A. 
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baumannii  isolates in South Korea (Ko, Suh et al. 2007). Colistin and other 
polymyxins target the lipid A component of lipopolysaccharide (LPS) of Gram 
negative bacteria during initial binding of the outer membrane. Mutations in the 
lipid A biosynthesis genes lpxA, lpxC, and lpxD can result in loss of ability to 
produce lipid A and therefore LPS. This prevents the interaction of colistin with 
LPS in colistin resistant A. baumannii isolates (Moffatt, Harper et al. 2010). An 
alternative mechanism of resistance was identified by Beceiro et al. who 
observed mutations in pmrB and upregulation of pmrAB leading to 
modification of lipid A and consequently colistin resistance (Beceiro, Llobet et 
al. 2011). 
- Carbapenems are one of the most valuable treatment options against MDR 
Acinetobacter. This class of β-lactams show good bactericidal activity against 
β-lactamase producing MDR Acinetobacter isolates (Fishbain and Peleg 
2010). However, increasing resistance to imipenem and meropenem has been 
observed in the last decade (Karageorgopoulos and Falagas 2008). 
Resistance to carbapenems is most commonly due to production of class D β-
lactamases e.g. OXA-51-like, and OXA-23-like enzymes (Turton, Ward et al. 
2006; Corvec, Poirel et al. 2007), increased production of multi-drug efflux 
pumps, such as AdeABC (Magnet, Courvalin et al. 2001; Huang, Sun et al. 
2008), and decreased permeability due to reduced expression of porins such 
as CarO (Ravasi, Limansky et al. 2011). Carbapenem resistant isolates are 
often resistant to other classes of antibiotics, leaving polymyxins and 
tigecycline as the only remaining treatment options. A 2007 study of 
antimicrobial susceptibility in isolates collected from around the world identified 
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susceptibility to imipenem ranging from 60.6% in Latin America to 88.6% in 
North America. Susceptibility was also high in Europe (85.9%), whereas 
susceptibility rates in Asia were moderate to low (69.2%) (Reinert, Low et al. 
2007). Since then, various studies have highlighted the emergence of 
carbapenem resistant isolates in the clinical setting (e.g. Scott, Deye et al. 
2007; Enoch, Summers et al. 2008; Lee, Fung et al. 2011; Kempf and Rolain 
2012). However, susceptibility data based on a particular carbapenem 
antibiotic cannot be generalised to all drugs in this class. Differing imipenem 
and meropenem resistance levels have been observed in clinical isolates 
(Ikonomidis, Pournaras et al. 2006). Misinterpreted susceptibility results can 
also give rise to dire consequences;  based on susceptibility to imipenem, a 
fatal case of A. baumannii pneumonia by a meropenem resistant isolate was 
treated with meropenem (Lesho, Wortmann et al. 2005). 
- Tigecycline is a member of a relatively new class of antimicrobials, the 
glycyclines, and is a semi-synthetic modified minocycline (Neonakis, 
Spandidos et al. 2011). Good in vitro activity has been demonstrated against 
595 clinical isolates of Acinetobacter spp. isolated throughout the UK 
(Henwood, Gatward et al. 2002) and global studies have shown MIC90 values 
of 1-2 µg/ml (Reinert, Low et al. 2007; Garrison, Mutters et al. 2009). There is 
a shortage of clinical studies investigating the activity of tigecycline, although a 
good clinical and microbiological response to tigecycline treatment of MDR 
Acinetobacter has been observed in some cases (Poulakou, Kontopidou et al. 
2009). Vasilev et al. identified a cure rate of 82.4% for resistant A. baumannii 
infections in a multicentre study (Vasilev, Reshedko et al. 2008). However, 
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Gordon et al. observed microbiological clearance of the infection in only 68% 
of cases in a retrospective study of tigecycline treated A. baumannii infections 
in a UK hospital. This result suggests that tigecycline monotherapy may not 
always be appropriate (Gordon and Wareham 2009). Due to this lack of 
clinical evidence, breakpoint concentrations to define resistance have not yet 
been established by CLSI, EUCAST or BSAC for this antibiotic class. 
Treatment failure has also been observed with tigecycline therapy. An 
increase in MICs often developed during therapy, after only three weeks 
exposure to the drug (Reid, Grim et al. 2007). Evaluation of tigecycline 
treatment in unrelated studies of patients with MDR A. baumannni infections 
also identified single A. baumannii isolates that developed resistance during 
treatment (Schafer, Goff et al. 2007; Anthony, Fishman et al. 2008). 
Tigecycline diffuses rapidly into tissues resulting in low mean peak serum 
concentrations at recommended doses. As a consequence, therapeutic failure 
is possible, even with susceptible isolates, and so tigecycline is not 
recommended for bacteraemia infections (Fishbain and Peleg 2010).  
 
1.3.1. Synergistic antibiotic combinations 
Due to the increase in the occurrence of MDR Acinetobacter and the increasingly 
limited spectrum of antibiotics available for treatment, there have been numerous 
attempts to identify synergistic combinations of antibiotics to use in the treatment of 
this organism. However, many of these studies have been conducted in vitro or in 
animal models and there are few clinical studies to confirm their findings. Most work 
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focuses on combinations that increase the efficacy of last line drugs such as 
carbapenems, tigecycline and colistin. Sheng et al. used time kill studies to identify 
synergism between imipenem and colistin, tigecycline, amikacin and ampicillin-
sulbactam against carbapenem resistant Acinetobacter species (Sheng, Wang et al. 
2011). Synergy has also been observed with a combination of colistin and 
glycopeptide antibiotics vancomycin and teicoplanin, which are usually associated 
with the treatment of Gram-positive infections (Gordon, Png et al. 2010; Wareham, 
Gordon et al. 2011). Clinical data comes from a limited number of studies and these 
do not always support the findings of in vitro studies. In a cohort study, Falagas et al. 
found that cure of infection was not improved with colisitin-meropenem combination 
therapy compared with colistin monotherapy (Falagas, Rafailidis et al. 2006). 
Nonetheless, there are some clinical studies that identify a synergistic effect with 
antibiotic combinations; a carbapenem and ampicillin-sulbactam combination has 
been shown to give a more favourable outcome than carbapenem monotherapy in a 
retrospective study of MDR A. baumannii bacteraemia infections in Taiwan (Kuo, Lai 
et al. 2007). A combination of rifampicin with both colistin and imipenem has shown 
high cure rates against carbapenem resistant A. baumannii infections in critically ill 
patients (Motaouakkil, Charra et al. 2006; Saballs, Pujol et al. 2006). 
 
1.4. Mechanisms of Antibiotic Resistance 
Acinetobacter spp. possess a wide range of antibiotic resistance mechanisms (Table 
1.2) (Peleg, Seifert et al. 2008; Roca, Espinal et al. 2012) , both innate and acquired, 
chromosomal and plasmid borne, allowing this bacterium to survive challenge by 
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many classes of antibiotics. The plasticity of the Acinetobacter genome allows it to 
adapt well to antibiotic pressure by capturing antibiotic resistance genes. An 86 kb 
genomic resistance island (AbaR1) has been identified in clinical isolates of MDR 
Acinetobacter spp., harbouring 45 genes conferring resistance to various classes of 
antibiotics including β-lactams, aminoglycosides, tetracycline and chloramphenicol  
(Fournier, Vallenet et al. 2006). This highlights the remarkable ability of this organism 
to acquire large mobile genetic elements, allowing it to rapidly adapt to its 
surroundings. The most widespread mechanisms of resistance in Acinetobacter are 
modification of the target, degradation or inactivation of the antibiotic and reduced 
permeability and active efflux of the agent. 
Target modification occurs in various systems in Acinetobacter. Mutations in gyrA 
and  parC are common, resulting in modified DNA gyrase or topisomerase and 
preventing fluoroquinolones from interacting with the DNA-gyrase complex 
(Hamouda and Amyes 2004). Phosphoethanolamine modification of lipid A was 
shown to lead to resistance to colistin in Acinetobacter by reducing the affinity of 
lipopolysaccharide (LPS) for the antibiotic (Beceiro, Llobet et al. 2011). 
β-lactamase enzymes confer resistance to various β-lactam antibiotics in 
Acinetobacter spp. by inactivation of the drug. Chromosomally encoded AmpC  
cephalosporinases can be found in all strains of A. baumannii and increased 
expression due to an upstream insertion sequence (IS) element, ISAba1, provides 
resistance to cephalosporins (Bou and Martinez-Beltran 2000; Hujer, Hujer et al. 
2006; Ruiz, Marti et al. 2007)  Extended spectrum β-lactamases (ESBLs) including 
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Table 1.2 . Resistance mechanisms previously identified in Acinetobacter 
species (Roca, Espinal et al. 2012). 









Metallo-β-lactamases IMP, VIM, SIM-1, NDM 
Other β-lactamases TEM, SHV, SCO-1, CARB, PER, 
VEB,      CTX-M, GES, KPC, OXA-2, 
10, 20, 37 
Decreased permeability CarO, 47 kDa OMP, 44 kDa OMP, 
37 kDa OMP, 33–36 kDa OMP, 22–
33 kDa OMP,  
HMP-AB, 43 kDa OMP 












Antimicrobial Resistance mechanism Protein 
Target binding site modification 16S rRNA methylases 
Efflux AdeABC, AbeM, AdeDE 
Quinolones Target site mutations GyrA/ParC 
Efflux pump AdeABC, AdeIJK, AdeFGH, AdeDE, 
AbeM, AbeS 
Chloramphenicol Efflux pump AdeABC, AdeIJK, AdeFGH, AdeDE, 
AdeXYZ, CmlA, CraA, AbeM, AbeS 
Tetracyclines Efflux pump TetA, TetB, AdeDE, AdeXYZ 
Ribosomal protection TetM 
Tigecycline Efflux pump AdeABC, AdeIJK 
Polymyxins Lipid A modification PmrCAB 
Loss of lipopolysaccharide LpxABC 








VEB (Carbonne, Naas et al. 2005), PER (Naas, Bogaerts et al. 2006), TEM 
(Endimiani, Luzzaro et al. 2007), SHV (Huang, Mao et al. 2004) and CTX-M 
(Nagano, Nagano et al. 2004) have all been described in A. baumannii, and can be 
found both plasmid and chromosomally encoded. Carbapenem hydrolysing enzymes 
are the most clinically relevant β-lactamases in Acinetobacter and both metallo-β-
lactamases (MBLs) and serine oxacillinases (OXA) have been identified in 
Acinetobacter (Poirel and Nordmann 2006). The most widespread of these are the 
OXA-type enzymes, which can be encoded chromosomally or on a plasmid. blaOXA-
51-like enzymes are naturally occurring in A. baumannii and encoded 
chromosomally. In the presence of an upstream promoter, ISAbaI, blaOXA-51-like 
genes provide intrinsic resistance to carbapenems (Turton, Ward et al. 2006; Turton, 
Woodford et al. 2006). blaOXA-51-like genes have a high prevalence worldwide and 
have been described in several studies (e.g. Héritier, Poirel et al. 2005; Coelho, 
Woodford et al. 2006; Hujer, Hujer et al. 2006; Turton, Woodford et al. 2006; Evans, 
Brown et al. 2007). blaOXA-23-like, blaOXA-24-like and blaOXA-58 like gene 
clusters have also been described as conferring carbapenem resistance in 
Acinetobacter (Donald, Scaife et al. 2000; Afzal-Shah, Woodford et al. 2001; Da 
Silva, Quinteira et al. 2004; Boo, Walsh et al. 2006; Coelho, Woodford et al. 2006; 
Corvec, Poirel et al. 2007). 
Loss of outer membrane proteins (OMPs) has also been implicated in Acinetobacter 
resistance to antibiotics. Acinetobacter possess few outer membrane porins, and 
intrinsic low level resistance can be partly attributed to low permeability of the outer 
membrane (Sato and Nakae 1991). Altered expression of OMPs in response to 
antibiotic challenge (Yun, Choi et al. 2008) can further reduce permeability to 
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antimicrobials and lead to MDR. Expression of OmpA38, OmpA32, CarO and OmpW 
is reduced in the presence of sub-MIC levels of tetracycline, suggesting a role for 
OMPs in tetracycline resistance (Yun, Choi et al. 2008). Loss of OMPs has been 
implicated in carbapenem resistance and is seen in clinical isolates worldwide (Bou, 
Cerveró et al. 2000; Tomás, Beceiro et al. 2005; Hwa, Subramaniam et al. 2010). 
 
1.5. Efflux  
Innate expression of efflux pumps in Acinetobacter allows a broad range of 
substrates to be removed from the cell, conferring resistance to various antibiotic 
classes. Increased expression of chromosomal efflux pumps and acquisition of 
additional efflux systems can then lead to MDR (Coyne, Courvalin et al. 2011). 
 
1.5.1. RND pumps 
The resistance nodulation division (RND) family are the most common efflux systems 
in MDR Acinetobacter and a number of pumps of this type have been identified in 
species belonging to the Acb complex. RND pumps in Gram negative bacteria 
comprise of three components, forming a tripartite pump. The efflux protein is located 
in the inner membrane, the OMP channel spans the outer membrane and a 
periplasmic accessory protein links the two (Figure 1.1) (Piddock 2006). There is 
often a high level of homology between proteins in this family and RND pump 
proteins identified in A. baumannii show some similarity to the MexXY-OprM and  
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Figure 1.1. Schematic representation of an assembled tripartite RND efflux 



















MexD previously characterised in Pseudomonas aeruginosa and MtrC from Neisseria 
gonorrhoeae (Magnet, Courvalin et al. 2001; Coyne, Courvalin et al. 2011). Most 
work carried out to date on the RND family of efflux pumps comes from the Courvalin 
team and is based on analysis of a single strain of A. baumannii, BM4454. This may 
not necessarily represent the paradigm for the species and further work is required to 
confirm these findings in other strains. 
AdeABC is the most well characterised RND system in Acinetobacter. Found in both 
A. baumannii and other clinically relevant species (Magnet, Courvalin et al. 2001; 
Roca, Espinal et al. 2011), it is chromosomally encoded but has only been identified 
in clinical isolates and only confers MDR when overexpressed (Magnet, Courvalin et 
al. 2001). MIC studies with BM4454 mutants in which the efflux pump proteins are 
not produced, reveal that substrates for this pump include aminoglycosides, β-
lactams, fluoroquinolones, tetracyclines, tigecycline, macrolides, chloramphenicol 
and trimethoprim (Magnet, Courvalin et al. 2001; Marchand, Damier-Piolle et al. 
2004). The role of AdeABC in efflux of carbapenems is still debated. Studies of 
clinical MDR isolates have shown a correlation between carbapenem resistance and 
overexpression of AdeABC (Héritier, Poirel et al. 2005; Huang, Sun et al. 2008). 
However, addition of efflux inhibitors carbonyl cyanide-m-chlorphenyl hydrazone 
(CCCP) did not affect carbapenem MICs in imipenem resistant clinical isolates from 
Greece (Pournaras, Markogiannakis et al. 2006). AdeABC is encoded as an operon, 
adeABC, and is regulated by the two-component system AdeRS. This system is 
encoded by adeRS, which is upstream and in the opposite direction to adeABC 
(Marchand, Damier-Piolle et al. 2004). AdeS is a sensor kinase and AdeR is its 
associated response regulator. Mutations in the AdeRS regulatory system are 
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associated with constitutive expression of AdeABC and MDR (Marchand, Damier-
Piolle et al. 2004; Peleg, Adams et al. 2007). Overexpression of AdeABC has also 
been seen in a clinical isolate due to the insertion of ISAba1 into adeS (Ruzin, 
Keeney et al. 2007). However, MDR due to AdeABC overexpression has been seen 
in the absence of AdeRS mutations, suggesting another mechanism causing 
increased pump activity is also possible (Peleg, Adams et al. 2007). Inactivation of 
adeB causes loss of resistance to multiple antibiotics (Magnet, Courvalin et al. 2001), 
whereas inactivation of adeC does not have the same effect. This suggests that 
AdeC is not essential for MDR and that other OMPs may be recruited by AdeAB 
(Marchand, Damier-Piolle et al. 2004). 
AdeIJK is found only in A. baumannii and has not been observed in any of the other 
members of the Acb complex. AdeJ shows 57% identity with AcrB from Escherichia 
coli and confers innate MDR (Damier-Piolle, Magnet et al. 2008; Lin, Ling et al. 
2009). It exports β-lactams, fluoroquinolones, tetracyclines, tigecycline, lincosamides, 
rifampicin, chloramphenicol, co-trimoxazole, novobiocin and fusidic acid, but not 
aminoglycosides in BM4454 (Damier-Piolle, Magnet et al. 2008; Coyne, Guigon et al. 
2010). AdeIJK can only be expressed at low levels in A. baumannii BM4454 and in E. 
coli, once expression reaches threshold levels the pump becomes toxic to the host 
(Damier-Piolle, Magnet et al. 2008; Coyne, Guigon et al. 2010). AdeIJK is encoded 
by the adeIJK operon. It is likely that the expression of this operon is regulated by a 
global mechanism as no local regulatory genes have yet been identified (Coyne, 
Guigon et al. 2010). 
AdeFGH is encoded by the adeFGH operon but is not expressed in wild type 
Acinetobacter and so does not contribute to intrinsic resistance (Coyne, Rosenfeld et 
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al. 2010). Overexpression of the pump in BM4454 led to resistance to 
fluoroquinolones, chloramphenicol, trimethoprim, clindamycin, tetracyclines, 
tigecycline and sulfamethoxazole (Coyne, Rosenfeld et al. 2010). Spontaneous MDR 
mutants selected from BM4652 (BM4454ΔadeABCΔadeIJK) on norfloxacin and 
chloramphenicol show mutations in a putative LysR-type transcriptional regulator, 
AdeL, located upstream of adeFGH. It is proposed that these mutations cause a 
constitutive phenotype, leading to increased expression of the AdeFGH efflux system 
(Coyne, Rosenfeld et al. 2010). 
AdeDE was identified as a novel RND efflux system in A. pittii by Chau et al. (Chau, 
Chu et al. 2004). Encoded by adeDE, no OMP gene was found to be encoded as 
part of this operon. It is suggested that AdeDE recruits an OMP encoded elsewhere 
on the chromosome (Chau, Chu et al. 2004). Inactivation of AdeE in a clinical isolate 
reduced susceptibility to aminoglycosides, carbapenems, ceftazidime, 
fluoroquinolones, erythromycin, tetracycline, rifampin and chloramphenicol (Chau, 
Chu et al. 2004). Although initially described in A. pittii, AdeDE has also been 
observed in A. nosocomialis and Acinetobacter gsp 17. However, prevalence is still 
highest in A. pittii, with 70% of clinical isolates (n=83) studied containing the adeDE 
operon (Chu, Chau et al. 2006). 
AdeXYZ is the other RND pump found in Acinetobacter spp. other than A. 
baumannii. It was identified in 90% of A. pittii isolates (n=83) tested in a study of 
blood culture isolates in China and was also been observed in A. nosocomialis and 
A. gsp. 17 (Chu, Chau et al. 2006). Although AdeXYZ has not been well 
characterised, the pump shows high homology with AdeIJK, suggesting a similar 
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function and possibly substrate range (Chu, Chau et al. 2006; Damier-Piolle, Magnet 
et al. 2008; Coyne, Courvalin et al. 2011). 
1.5.2. Non-RND pumps 
Acinetobacter spp. also possess a number of chromosomally encoded non-RND 
efflux systems: CraA contributes to intrinsic resistance to chloramphenicol (Roca, 
Marti et al. 2009), AmvA is a major facilitator superfamily (MFS) pump that exports 
erythromycin (Rajamohan, Srinivasan et al.), AbeM is a member of the multidrug and 
toxic compound extrusion (MATE) family and has a suggested role in resistance to a 
range of antibiotics and dyes (Su, Chen et al. 2005), and AbeS is a small multidrug 
resistance (SMR) efflux pump involved in chloramphenicol, fluoroquinolone, 
erythromycin, novobiocin and dye and detergent resistance (Srinivasan, Rajamohan 
et al. 2009). 
Various acquired efflux systems have also been identified in Acinetobacter spp., 
carried either on plasmids, transposons or resistance islands (Vila, Marti et al. 2007). 
Most common are pumps of the MFS type that give resistance to tetracycline. The 
TetA pump, has been observed in 13.6% of tetracycline resistant strains (n=59) of A. 
baumannii and the TetB pump, conferring tetracycline and minocycline resistance, in 
66% (n=59) (Marti, Fernandez-Cuenca et al. 2006). In a study of 32 clinical isolates 
of A. baumannii conducted by Mak et al., 28 contained the tetB gene whilst tetA was 
not present in any isolate (Mak, Kim et al. 2009). The TetG and TetR MFS pumps 
have also been observed in Acinetobacter spp., as part of the acquired ISAbaR1 
resistance island (Fournier, Vallenet et al. 2006). The MFS pumps CmlA and FloR, 
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and the SMR pump QacE are also acquired on the ISAbaR1 resistance island 
identified in A. baumannii AYE (Fournier, Vallenet et al. 2006). 
 
1.6. Measurement of antibiotic accumulation by Acinetobacter 
1.6.1. Background to this project 
Acinetobacter is rapidly emerging as a highly significant pathogen in hospitals 
worldwide. Its propensity to acquire foreign resistance determinants and upregulate 
intrinsic mechanisms allows this organism to adapt and survive in the clinical setting. 
Key to its ability to resist challenge by a wide range of antibiotics is the 
overexpression of efflux pumps. The present study is part of a collaborative 
programme of research to characterise efflux pumps that confer clinically relevant 
MDR in order to guide antimicrobial therapy. 
1.6.2. Hypotheses 
 Previously uncharacterised putative efflux pumps revealed through 
comparative genomics contribute towards antimicrobial resistance in 
Acinetobacter species. 
 Deletion of efflux pump genes, or inhibition of efflux pumps, in clinical isolates 
of A. baumannii will lead to reduced efflux and therefore reduced resistance to 
clinically relevant antibiotics. 
 
1.6.3. Aims and Objectives 
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1. Adapt the method for measuring the accumulation of Hoechst 33342 by 
Enterobacteriaceae for use with A. baumannii. 
2. Determine whether the levels of accumulation of Hoechst 33342 by A. 
baumannii are comparable with those of ethidium bromide and norfloxacin. 
3. To use specific pump deletion mutants to 
a. determine the MICs of selected antimicrobial compounds to aid identification 
of efflux pumps that efflux clinically relevant antibiotics. 
b. measure the levels of efflux in pump deletion mutants and to identify 










2. Materials and Methods 
2.1. Bacterial strains, growth, storage and identification 
A. baumannii strain AYE was selected as a reference MDR strain for use in this 
study. AYE is epidemic in France and is associated with a mortality of 26% in 
infected patients (Poirel, Menuteau et al. 2003). This strain was chosen as a fully 
annotated genome sequence is available and has shown AYE to contain 52 antibiotic 
resistance genes, including an 86kb resistance island, harbouring 45 antibiotic 
resistance genes (Fournier, Vallenet et al. 2006). Bioinformatic analysis using 
AciBase revealed that AYE contained all previously described efflux pumps and the 
majority of predicted efflux pumps (L. Evans & L. J. V. Piddock, unpublished data). 
Clinical isolates cultured from hospital infections in Singapore were provided by Kim 
Lee Chua. R1, R2 and R3 were representative of antibiotic resistant isolates, and S1, 
S2 and S3 were representative of antibiotic susceptible isolates (Table 2.1). Efflux 
pump deletion mutants were created in R2 and S1 by Kim Lee Chua (manuscript in 
preparation). These isolates were selected as representative of antibiotic resistant 
and susceptible clinical isolates in infections in Singapore hospitals. adeFGH, adeIJK 
and A1S_1649 were deleted individually and in combination to give strains R2-
ΔadeFGH, R2-ΔadeIJK, R2-ΔadeFGHΔadeIJK, and R2ΔadeFGHΔP7 (Table 2.1). 
‘Pump 7’ (P7) is a putative RND family drug transporter identified in ATCC17978. 
adeB was deleted in S1 to give S1ΔadeB. AB211 and AB211ΔadeB were provided 
by Mike Hornsey (Queen Mary's School of Medicine and Dentistry, London). AB211 
is a tigecycline resistant, post-therapy clinical isolate. AB211ΔadeB was created by 
Hornsey et al. by insertional inactivation of adeB in AB211. 
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Table 2.1. Strains used in this study 
Code Source Reference 
AYE MDR clinical isolate (France) Poirel et al., 2003 
R1 Resistant clinical isolate (Singapore) Kim Lee Chua, unpublished 
R2 Resistant clinical isolate (Singapore) Kim Lee Chua, unpublished 
R3 Resistant clinical isolate (Singapore) Kim Lee Chua, unpublished 
S1 Susceptible clinical isolate (Singapore) Kim Lee Chua, unpublished 
S2 Susceptible clinical isolate (Singapore) Kim Lee Chua, unpublished 
S3 Susceptible clinical isolate (Singapore) Kim Lee Chua, unpublished 
S1 ΔadeB adeB pump deletion mutant in S1 Kim Lee Chua, unpublished 
R2ΔadeFGH adeFGH pump deletion mutant in R2 Kim Lee Chua, unpublished 
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R2ΔadeIJK adeIJK pump deletion mutant in R2 Kim Lee Chua, unpublished 
R2ΔadeFGHΔadeIJK adeFGH and adeFGH double pump deletion mutant in R2 Kim Lee Chua, unpublished 
R2ΔadeFGHΔP7 adeFGH and P7 double pump deletion mutant in R2 Kim Lee Chua, unpublished 
S1ΔadeB adeB pump deletion mutant in S1 Kim Lee Chua, unpublished 
AB211 Tigecycline resistant clinical isolate (UK) Hornsey et al., 2011 




All strains were routinely grown on Luria-Bertani (LB) agar (Sigma-Aldrich Ltd., UK), 
supplemented with appropriate antibiotics where necessary, and incubated overnight 
at 37°C. Overnight cultures were grown in LB broth (Sigma-Aldrich Ltd., UK), 
supplemented with appropriate antibiotics where necessary, and incubated overnight 
at 37°C with aeration (Table 2.2). Purity of cultures was confirmed by growth as 
opaque pink colonies on MacConkey agar. Colonies were confirmed as Gram-
negative coccobacilli by Gram staining and microscopic observation. All strains and 
isolates were confirmed as Acinetobacter species by a gyrB PCR developed by 
Higgins et al. (Higgins, Wisplinghoff et al. 2007; Higgins, Lehmann et al. 2010). This 
protocol uses seven primers in a multiplex PCR to produce different sized amplimers, 
allowing differentiation between A. baumannii, A. calcoaceticus, A. pittii and A. 
nosocomialis. All primers were produced by Invitrogen (Invitrogen Ltd., UK; listed in 
Table 2.3). All primers were re-hydrated with UltraPure water (Invitrogen, UK) to a 
concentration of 100 μM; 25 μM working stock solutions of each primer were made. 
All primers were stored at -20°C. Polymerase chain reactions (PCR) were set up 
using 22 µl of 1.1 x ReddyMix  PCR Master Mix (Thermo Scientific, UK, AB – 
0794/B). A 25 µM stock of each of the seven primers was combined in equal volumes 
and 2 µl of this stock and 1 µl of whole cell lysate was added to the master mix. 
Whole cell lysates were prepared by adding a loopful of bacterial culture from an LB 
agar plate to 100 µl of sterile water and heating at 99ºC for ten minutes. The initial 
denaturation step was carried out at 94°C for two minutes. This was followed by 25 
cycles of denaturation at 94°C for one minute, annealing at 60°C for 30 seconds and 
elongation at 72°C for one minute. This was followed by a final elongation stage at 
72°C for ten minutes (Table 2.4, PCR 1). Products were separated by agarose gel 
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electrophoresis in 1% Tris-Boric acid-EDTA (TBE) at 100 volts. Gels were prepared 
by adding 1 g of electrophoresis grade agarose (Invitrogen Ltd, UK, 15510-027) to 50 
ml of 1% TBE. The agarose was dissolved by heating in a 650 W microwave for 
approximately 90 seconds. Another 50 ml of TBE was then added before ethidium 
bromide was added to a final concentration of 0.1 µg/ml. The molten agarose was 
poured into a gel tray and allowed to set. Five microlitres of each sample was then 
loaded onto the gel along with a DNA ladder (Bioline). 
 
2.2. Verification of efflux pump gene deletions 
Primers designed by Kim Lee Chua (data unpublished) were used to confirm gene 
deletions in R2ΔadeFGH, R2ΔadeIJK, R2ΔadeIJKΔadeFGH and R2ΔadeFGHΔP7 
(Table 2.3). Primers were external to the deleted genes and designed to produce 
different sized amplimers with parental and mutant strains. Three PCRs were carried 
out with each pump deletion mutant and the parental strain, R2, to check for deletion 
of adeIJK, adeFGH and the pump 7 gene in each. The reaction contained 11 µl 
Reddymix Extensor PCR Mastermix (1.1) (Thermo Scientific, UK - AB-0794/B), 11 µl 
sterile water, 1 µl whole cell lysate and 1 µl forward primer and 1 µl reverse primer 
(25 µM) for each PCR (Table 2.4, PCR 2, 3, 4). The initial denaturation step was two 
minutes at 94ºC followed by 30 cycles of denaturation at 94ºC for ten seconds, 
annealing at 50ºC for 30 seconds and elongation at 68ºC for five minutes. The final 
denaturation step was for seven minutes at 68ºC. Products were separated by 
electrophoresis on a 1 % agarose gel as described previously (Section 2.1).
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Table 2.2. Antibiotics, dyes and EPIs used in this study 
Agent Solvent  Supplier 
Nalidixic acid Distilled water Sigma-Aldrich, UK 
Ciprofloxacin SDW and acetic acid Sigma-Aldrich, UK 
Kanamycin Distilled water Sigma-Aldrich, UK 
Gentamicin Distilled water Sigma-Aldrich, UK 
Ceftazidime 0.1 M sodium hydroxide Sigma-Aldrich, UK 
Imipenem n/a Biomerieux, UK 
Meropenem n/a Biomerieux, UK 
Piperacillin Distilled water Pfizer, UK 
Ampicillin 1 M Sodium bicarbonate Sigma-Aldrich, UK 
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Sulbactam Distilled water Pfizer, UK 
Chloramphenicol 70 % methanol Sigma-Aldrich, UK 
Tigecycline Distilled water Pfizer, UK 
Tetracycline Distilled water Sigma-Aldrich, UK 
Erythromycin 100 % ethanol Sigma-Aldrich, UK 
Colistin Distilled water Sigma-Aldrich, UK 
Trimethoprim 70 % ethanol Sigma-Aldrich, UK 
Hoechst Distilled water Sigma-Aldrich, UK 
Ethidium bromide Distilled water Sigma-Aldrich, UK 
Norfloxacin Acetic acid and distilled water Sigma-Aldrich, UK 
CCCP Dimethyl sulfoxide Sigma-Aldrich, UK 
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PAβN Distilled water Sigma-Aldrich, UK 












Table 2.3. Primers used in this study 
Primer 
number 
Description Sequence Reference 
1079 A. baumannii gyrB forward GTTCCTGATCCGAAATTCTCG Higgins et al., 2007 
1080 A. baumannii and A. nosocomialis gyrB 
forward 
CACGCCGTAAGAGTGCATTA Higgins et al., 2007 
1081 A. baumannii and A. nosocomialis gyrB 
reverse 
AACGGAGCTTGTCAGGGTA Higgins et al., 2007 
1082 A. calcoaceticus gyrB forward GACAACAGTTATAAGGTTTCAGGTG Higgins et al., 2010 
1083 A. calcoaceticus gyrB reverse CCGCTATCTGTATCCGCAGTA Higgins et al., 2010 
1084 A. pittii gyrB forward GATAACAGCTATAAAGTTTCAGGTGGT Higgins et al., 2010 
1085 A. pittii gyrB reverse CAAAAACGTACAGTTGTACCACTGC Higgins et al., 2010 
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1479 adeB forward check GCAATCACCAAAGGAATTAC Kim Lee Chua 
(unpublished) 
1480 adeB reverse check ATCTATTGGGCTGATATTAC Kim Lee Chua 
(unpublished) 
1481 adeI forward check GCGATAAAGTCATTGTTGATG Kim Lee Chua 
(unpublished) 
1482 adeK reverse check GTTCTGTGTAATCTGATATTGCTG Kim Lee Chua 
(unpublished) 
1483 adeFGH external check ATTAAGTTTTGAGCGTATAAGCTTC Kim Lee Chua 
(unpublished) 




1104 Pump 7 external check ACAGTCCGCAGCAGAGATTT Kim Lee Chua 
(unpublished) 












Table 2.4. Parameters and primers used for PCRs 


















94ºC (2 min) 94ºC (1 min) 60ºC (30 sec) 72ºC (1 min) 72ºC (10 min) 25 
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94ºC (2 min) 94ºC (10 sec) 54ºC (30 sec) 68ºC (5 min) 68ºC (7 min) 30 




94ºC (2 min) 94ºC (10 sec) 54ºC (30 sec) 68ºC (5 min) 68ºC (7 min) 30 




94ºC (2 min) 94ºC (10 sec) 54ºC (30 sec) 68ºC (5 min) 68ºC (7 min) 30 









2.3. Phenotypic characterisation of clinical isolates and efflux pump deletion 
mutants 
The phenotypes of susceptible clinical isolates S1, S2 and S3 were compared with 
those of resistant clinical isolates R1, R2 and R3. The effect of the deletion of efflux 
pump genes in mutants R2ΔadeFGH, R2ΔadeIJK, R2ΔadeFGHΔadeIJK and 
R2ΔadeFGHΔP7 was determined by comparing the phenotype to that of the parental 
strain, R2. The effect of the deletion of efflux pump gene adeB was determined by 
comparing the phenotype of S1ΔadeB to that of the parental strain, S1. 
 
2.3.1. Bacterial growth kinetics 
Bacterial strains were grown with aeration in LB broth at 37°C overnight. Bacterial 
cultures were diluted 1:100 in sterile LB broth and 100 µl of this suspension was 
added to each well of a clear 96 well microtitre tray. Optical density (OD) at an 
absorbance of 600 nm was measured over 16 hours in the BMG FLUOstar Optima 
(BMG labtech, UK) at 37°C. Each experiment included three biological replicates and 
three technical replicates of each bacterial strain. The FLUOstar is sensitive to an OD 
600 nm of between 0.0 and 4.0 and reproducibility is ±0.010 for the OD range of 0.0-
2.0 (www.BMG-labetech.com). 
 
2.3.2. Determination of the minimum inhibitory concentrations of antibiotics 
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The MICs of antibiotics and efflux inhibitors (EIs) (Table 2.2) were determined by the 
agar doubling dilution method according to the British Society for Antimicrobial 
Chemotherapy (BSAC) standard methodology (Andrews 2001). Stock solutions of 
10,000 µg/ml of antibiotics were made up and appropriate amounts added to 20 ml of 
cooled, molten Iso-sensitest agar (Oxoid, UK) in sterile universals. This was 
dispensed aseptically into petri dishes and allowed to set. Overnight cultures of each 
bacterial strain to be tested were diluted 1:100 to give approximately 107 CFU/ml.  
Each agar plate was inoculated with 1 µl of diluted culture giving approximately 104 
colony forming units (CFU) per spot. Plates were incubated overnight at 37ºC and 
read according to BSAC guidelines. The MIC was determined as the lowest 
concentration of antibiotic that inhibited visible growth (Andrews 2001).  MICs of 
imipenem and meropenem were determined by E-test (Biomerieux, UK). Colonies 
grown overnight on LB agar were emulsified in sterile water to a concentration of 
approximately 108 CFU/ml. A sterile swab was soaked in the suspension and the 
surface of an iso-sensitest agar plate streaked in three directions. The plate was 
allowed to dry for approximately 15 minutes before E-test gradient strips were 
positioned on the surface. Plates were incubated overnight at 37ºC and read 
according to the manufacturer’s instructions. Resistance was determined using 
BSAC recommended breakpoint concentrations for A. baumannii. MDR strains were 
defined as those resistant to three or more antimicrobial classes.  
 
2.3.3. Development of a Hoechst 33342 accumulation assay to measure efflux 
in A. baumannii 
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The bisbenzamide dye Hoechst (H) 33342 is a fluorescent dye that is readily taken 
up by living cells and fluoresces with a high quantum yield upon binding to DNA and 
when in the hydrophobic environment of the lipid membrane.  A H33342 
accumulation assay has previously been used to measure efflux and identify MDR 
Gram-negative Enterobacteriaceae (Coldham, Webber et al. 2010). This assay was 
modified for use with A. baumannii and used to measure differences in efflux 
between clinical isolates R1-3 and S1-3, pump deletion mutant AB211ΔadeB and its 
parental strain AB211 and pump deletion mutants S1ΔadeB, R2ΔadeFGH, 
R2ΔadeIJK, R2ΔadeFGHΔadeIJK and R2ΔadeFGHΔP7 and the parental strains, S1 
and R2. 
The assay was initially developed using isolates R1, R2, R3, S1, S2 and S3. First, 
viability of the clinical isolates at 1x, 2x and 4x H33342 concentrations used in the 
assay was determined. A stock solution of H33342 was made up and appropriate 
amounts added to 20 ml of cooled, molten Iso-sensitest agar (Oxoid, UK) in sterile 
universals. This was dispensed aseptically into petri dishes and allowed to set. 
Overnight cultures of each bacterial strain to be tested were diluted 1:100 to give 
approximately 107 CFU/ml.  Each agar plate was inoculated with 1 µl of diluted 
culture giving approximately 104 CFU/spot. Plates were incubated overnight at 37º 
and plates were examined for inhibition of growth. 
Clinical isolates R1, R2, R3, S1, S2 and S3, and reference strain AYE, were used to 
assess the suitability of the H33342 accumulation assay for determining differences 
in efflux between clinical isolates of A. baumannii. The ability of the assay to identify 
altered efflux in strains lacking efflux pumps was assessed with AB211 and efflux 
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pump deletion mutant AB211ΔadeB (Hornsey, Loman et al. 2011). Bacterial strains 
to be tested were grown with aeration in LB broth at 37°C overnight. A 4% inoculum 
(120 µl in 3 ml) of bacterial culture was added to fresh LB broth. This suspension was 
incubated with aeration at 37°C until the cells reached mid-logarithmic phase. Cells 
were harvested by centrifugation at 2200 x g in a Hereaus Megafuge 40R (Thermo 
Scientific, UK) for ten minutes at room temperature and resuspended in phosphate 
buffered saline (PBS) at room temperature. The OD at 600 nm was adjusted to either 
0.1, 0.2, 0.3 or 0.5 and 180 µl of the cell suspension was dispensed into the wells of 
a black microtitre tray (Corning, Amsterdam). Assays with cell suspensions of varying 
optical density were carried out to assess the optimal number of bacterial cells to use 
in the assay. A 25 µM Hoechst H33342 stock was prepared to give a final 
concentration of 2.5 μM and loaded into the FLUOstar OPTIMA for injection after an 
initial reading. Fluorescence was measured over 117 minutes at excitation and 
emission wavelengths of 350 nm and 461 nm respectively in a FLUOstar OPTIMA. 
The level at which maximum fluorescence was reached and remained unchanged 
within the time period of the assay was taken as the steady state accumulation level. 
Student’s t-tests were carried out to compare the steady state accumulation level of 
AB211ΔadeB with the parental strain, AB211; P values <0.05 were taken as 
significant.  In order to quantitatively compare the efflux rate of the strains, the time 
taken for a 4 fold increase in fluorescence to occur after H33342 injection was 
calculated. Each assay was repeated three times with two biological replicates. 
The assay was developed further for use with the efflux inhibitors (EIs) carbonyl 
cyanide-m-chlorophenyl hydrazone (CCCP) and phenyl-arginine-β-naphthylamide 
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(PAβN). Concentrations of EIs non-inhibitory to the growth of A. baumannii clinical 
isolates, R1, R2, R3, S1, S2 and S3 were determined by MIC determination and 
growth kinetic assays. MICs were carried out by the agar doubling dilution method as 
previously described (Section 2.3.2). Growth kinetics in the presence of sub-MIC 
concentrations of EIs were then carried out to simulate conditions in the H33342 
accumulation assay and ensure no inhibition of growth. Bacterial strains to be tested 
were grown with aeration in LB broth at 37°C overnight. A 4% inoculum (120 µl in 3 
ml) of bacterial culture was added to fresh LB broth. This suspension was incubated 
with aeration at 37°C until the cells reached mig-logarithmic phase, which is equal to 
an OD at 600 nm of 0.6. Cells were harvested by centrifugation at 2200 x g in a 
Hereaus Megfuge 40R for ten minutes at room temperature and resuspended in 3 ml 
sterile LB broth. The OD at 600 nm of the suspension was measured and adjusted to 
0.5 to standardise the number of cells in each culture and to simulate the conditions 
used in the H33342 accumulation assay. 176 µl of this suspension was added to 
each well of a clear 96 well microtitre tray, along with 4 µl of EI at the required 
concentration. OD at an absorbance of 600 nm was measured over 16 hours in a 
BMG FLUOstar OPTIMA (BMG, UK) at 37°C. Each experiment included three 
biological replicates and three technical replicates of each bacterial strain. Student’s 
t-test were carried out to determine significant difference between growth with and 
without EI; P values <0.05 were taken as significant. Concentrations of EIs that did 
not restrict growth in the two hour time period of the H33342 accumulation assay 




2.3.4 Hoechst 33342 accumulation in efflux pump deletion mutants 
The assay was carried out as described previously (Section 2.3.3). After 
resuspension in PBS, bacterial strains were adjusted to an OD at 600 nm of 0.5 and 
either 180 µl of the cell suspension, or 176 µl of cell suspension and 4 µl of EPI at the 
required concentration was dispensed into the wells of a black microtitre tray. 
Concentrations of 50 µM CCCP and  100 µM PAβN were found previously to be non-
inhibitory to growth and were used in this and all subsequent assays. A 25 µM 
H33342 stock solution was prepared and loaded into the FLUOstar OPTIMA for 
injection after an initial reading; this gave a final concentration of 2.5 μM. 
Fluorescence was measured over 117 minutes at excitation and emission 
wavelengths of 350 nm and 461 nm, respectively, in a FLUOstar OPTIMA. The level 
at which maximum fluorescence was reached and remained unchanged within the 
time period of the assay was taken as the steady state accumulation level. As 
fluorescence is an arbitrary number and can vary between assays, fold change in 
fluorescence of mutants compared to the parent strain, and of strains with EI 
compared to without EI was calculated to enable  comparison between individual 
runs. Student’s t-tests were carried out to compare the steady state accumulation 
level of each mutant with the parental strain and of each strain with EI with the same 
strain without EI; P values <0.05 were taken as significant. Each assay was repeated 
at least three times with two biological replicates. 
 
2.3.5 Ethidium bromide accumulation 
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Bacterial strains to be tested were grown with aeration in LB broth at 37°C overnight. 
A 4% inoculum (120 µl in 3 ml) of bacterial culture was added to fresh LB broth. This 
suspension was incubated with aeration at 37°C until the cells reached mid-
logarithmic phase, which is equal to an OD at 600 nm of 0.6. Cells were harvested by 
centrifugation at 2200 x g in a Hereaus Megafuge 40R for 10 min at 4ºC and 
resuspended in 1M sodium phosphate buffer with 5 % glucose. The OD at 600 nm 
was adjusted to 0.5 and either 180 µl of the cell suspension, or 176 µl of cell 
suspension and 4 µl of EI at the required concentration was dispensed into the wells 
of a black microtitre tray. A 1 mM ethidium bromide stock was prepared and loaded 
into a FLUOstar OPTIMA for injection after an initial reading, to a final concentration 
of 0.1 mM. Fluorescence was measured over 117 minutes at excitation and emission 
wavelengths of 530 nm and 600 nm respectively in a FLUOstar OPTIMA. The level at 
which maximum fluorescence was reached and remained unchanged within the time 
period of the assay was taken as the steady state accumulation level. As 
fluorescence is an arbitrary number and can vary between assays, fold change in 
fluorescence of mutants compared to the parent strain, and of strains with EI 
compared to without EI was calculated to enable  comparison between individual 
runs. Student’s t-tests were carried out to compare the steady state accumulation 
level of each mutant with the parental strain; P values <0.05 were taken as 
significant.  Each assay was repeated three times with two biological replicates. 
 
2.3.6 Norfloxacin accumulation 
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Dry cell weights were determined for parental strain, R2, and reference strain, AYE. 
Bacterial strains were grown with aeration in Iso-sensitest broth at 37°C overnight. A 
4% inoculum (10 ml in 250 ml) of bacterial culture was added to fresh Iso-sensitest 
broth. This suspension was incubated with aeration at 37°C.  20 ml samples were 
taken at an OD at 660 nm of 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.65, 0.7, 0.75, 0.8 and 0.9 
and placed in dry, pre-weighed universal tubes. Samples were centrifuged at 2200 x 
g in a Hereaus Megafuge 40R for 10 min at room temperature and the supernatant 
discarded. Tubes containing pellet were placed in a desiccator and weighed every 24 
hours until weight reached a stable point (seven days). Cell weight per ml of culture 
was calculated and a standard curve of OD at 660 nm against dry cell weight was 
plotted. 
Bacterial strains to be tested were grown with aeration in iso-sensitest broth at 37°C 
overnight. A 4 % inoculum (10 ml in 250 ml) of bacterial culture was added to fresh 
Iso-sensitest broth and incubated with aeration at 37°C until the cells reached mid-
logarithmic phase, which is equal to an OD at 660 nm of 0.55. Cells were harvested 
by centrifugation at 4500 x g in a Hereaus Megafuge 40R for 20 minutes at 4ºC. Cells 
were resuspended and washed twice in 10 ml cold 50 mM phosphate buffer. Cells 
were resuspended to an OD at 660 nm of 20 in cold 50 mM phosphate buffer and 
incubated at 37ºC with stirring for ten minutes. At t=0, a 500 µl sample of each cell 
suspension was transferred to a tube containing 1 ml 50 mM phosphate buffer on ice 
and 10 µl of a 1000 µg/ml stock solution of norfloxacin was added to a final 
concentration of 10 µg/ml. To measure the effect of EIs on uptake, EIs were also 
added at t=0 if required. At t=300 seconds another 500 µl sample was transferred to 
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a microcapped centrifuge tube containing 1 ml 50 mM phosphate buffer on ice and all 
samples were centrifuged at 13,000 x g in a Hereaus Megafuge 40R for five minutes 
at 4ºC. Cell pellets were resuspended and washed twice in 1 ml cold 50 mM 
phosphate buffer to remove bound norfloxacin. Cell pellets were resuspended in 1 ml 
0.1 M glycine (pH 3) and incubated overnight at room temperature in the dark. 
Samples were then centrifuged at room temperature for five minutes at 13,000 x g. 
The supernatant was transferred to a fresh tube and centrifuged as before. Samples 
were diluted 1:100 in 0.1 M glycine (pH 3) and fluorescence was measured in an LS 
45 fluorescence spectrophotometer (Perkin Elmer) at an excitation and emission 
wavelength of 281 nm and 440 nm respectively. Standards of 0.001, 0.01 and 0.03 
µg/ml norfloxacin in 0.1 M glycine were used to calculate concentration of norfloxacin 
in each sample, and from this dry cell weight curves were used to calculate ng of 
norfloxacin per mg of bacterial cells. Student’s t-tests were carried out to compare 
concentrations of norfloxacin in each mutant with the parental strain, and of each 
strain with EI with the same strain without EI; P values <0.05 were taken as 










Chapter Three: Measurement of efflux in A. 














Chapter 3. Measurement of efflux in A. baumannii clinical isolates and efflux 
pump deletion mutants   
3.1. Background 
The bisbenzamide dye Hoechst (H) 33342 is a fluorescent dye that is readily taken 
up by living cells and fluoresces with a high quantum yield upon binding to DNA and 
when in the hydrophobic environment of the lipid membrane. This makes it an ideal 
fluorescent probe for the measurement of cellular accumulation. 
 
3.2. Aims and Hypotheses 
The aim was to assess the suitability of the H33342 accumulation method, previously 
used for the measurement of efflux in Enterobacteriaceae (Coldham, Webber et al. 
2010), for A. baumannii and to use it to measure efflux in clinical isolates and pump 
deletion mutants. The hypothesis was that this assay could be used to compare 
levels of efflux in different clinical isolates of A. baumannii and to identify a difference 
in efflux between pump deletion mutants and parental strains. 
 
3.3. Adaptation of the Hoechst 33342 accumulation method to measure dye 
accumulation in clinical isolates of A. baumannii 
3.3.1. Phenotypic characterisation of strains used to develop H33342 assay 
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All strains were confirmed as A. baumannii using a gyrB multiplex PCR (Table 2.4, 
PCR number 1) (primer positions shown in Appendix 1); each isolate produced a 294 
base pair (bp) amplicon and a 490 bp amplicon (Figure 3.1 and Table 3.1) 
characteristic of this species. 
3.3.1.1. Bacterial growth kinetics 
The generation time of antibiotic susceptible Singaporean clinical isolates was 
significantly lower than that of antibiotic resistant isolates (Figure 3.2 and Table 3.2). 
Generation time was lower than AYE in isolates S1, S2 and S3. Generation time was 
higher than AYE in isolates R1, R2 and R3. However, there was no significant 
difference in optical density at onset of stationary phase (500 min) between antibiotic 
susceptible isolates (S1, S2, S3) and antibiotic resistant isolates (R1, R2, R3). OD at 
600 nm at onset of stationary phase was higher in isolates S1 and S2 than strain 
AYE. OD at 600 nm at onset of stationary phase was lower in isolate R3 than in 
strain AYE. 
3.3.1.2. Antimicrobial susceptibility 
AYE, R1, R2 and R3 were multidrug resistant (MDR) clinical isolates, resistant to 
three or more classes of antibiotics including β-lactams, fluoroquinolones, 
aminoglycosides and carbapenems (Table 3.1). Strain AYE and isolates R1 and R3 
were susceptible to colistin (MIC ≤ 2). AYE, R2 and R3 were resistant to tigecycline. 
S1, S2 and S3 had resistance to fewer antibiotics. S1 and S3 were susceptible to 
ciprofloxacin, S2 and S3 were susceptible to colistin, S1 was susceptible to 
tigecycline, and S1, S2 and S3 were susceptible to carbapenems. 
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Figure 3.1. and Table 3.1. Confirmation of strains as Acinetobacter baumannii 
using a gyrB multiplex PCR. 
 
  
Lane Description Predicted fragment 
size (bp) 
Actual fragment size 
(bp) 
1 AB211 294 + 490 294 + 490 
2 AB211ΔadeB 294 + 490 294 + 490 
3 R1 294 + 490 294 + 490 
4 R2 294 + 490 294 + 490 
5 R3 294 + 490 294 + 490 
6 S1 294 + 490 294 + 490 
7 S2 294 + 490 294 + 490 
8 S3 294 + 490 294 + 490 
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9 AYE  294 + 490 294 + 490 
10 S1ΔadeB 294 + 490 294 + 490 
11 R2ΔadeFGH 294 + 490 294 + 490 
12 R2ΔadeIJK 294 + 490 294 + 490 
13 R2ΔadeFGHΔadeIJK 294 + 490 294 + 490 
14 R2ΔadeFGHΔP7 294 + 490 294 + 490 




Figure 3.2. Growth kinetics of clinical isolates R1, R2, R3, S1, S2 and S3 at 37°C 
as determined by optical density. 
 
Table 3.2. Generation times and optical density at onset of stationary phase 
(540 min) 
Strain Generation Time 
(min) 
OD 600 nm at onset of 
stationary phase (540 min) 
AYE 78 0.99 
S1 64 1.06 
S2 71 1.04 
S3 54 0.97 
R1 95 1.01 
R2 89 1.00 
R3 119 0.96 
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3.3.1.3. Growth in the presence of efflux inhibitors and toxicity of H33342 
To determine non-inhibitory concentrations of efflux inhibitors (EIs) for use in the 
H33342 accumulation assay, MICs of CCCP and PAβN against strain AYE and 
isolates S1, S2, S3, R1, R2 and R3 were determined (Table 3.3). MICs of both EIs 
were found to be lowest against S3 so this isolate was selected to determine growth 
kinetics in the presence of sub-MIC concentrations of EIs under the conditions of the 
H33342 accumulation assay. Concentrations of EIs that did not restrict growth in the 
two hour time period of the H33342 accumulation assay were used in all 
experiments. Concentrations of 50 µM CCCP and 100 µM PAβN had no effect on 
growth under conditions used in the H33342 assay (Figure 3.3). MICs of H33342 
showed that all strains grew at concentrations up to 128 µg/ml (Table 3.3), much 
higher than the 2.5 µM concentration used in the accumulation assay. 
 
3.3.2. Optimisation of the H33342 accumulation assay for measurement of 
efflux in clinical isolates and strain AYE 
Previous work in this laboratory has shown that different levels of accumulation of 
H33342 can be distinguished for different strains of Enterobacteriaceae with a 
H33342 concentration of 2.5µM (Coldham, Webber et al. 2010). Therefore, this 
concentration was selected for use in experiments with A. baumannii. Assays were 
carried out using cell cultures adjusted to an OD at 600 nm of either 0.1, 0.2, 0.3 or 
0.5. Cultures at an OD at 600 nm of 0.5 were found to produce measurable and  
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Table 3.3. MICs of a range of clinically relevant antibiotics and dyes against R1, 
R2, R3, S1, S2, S3 and AYE (µg/ml). 
Strain AYE S1 S2 S3 R1 R2 R3 
NAL >1024 8 32 32 1024 >1024 1024 
CIP 128 0.5 16 0.5 8 256 128 
NOR 128 4 32 8 64 128 128 
KAN >1024 1 512 1 >1024 >1024 >1024 
GEN 1024 1 2 64 >1024 >1024 256 
TAZ >1024 >1024 >1024 >1024 >1024 >1024 >1024 
IMPa 0.38 0.094 0.094 0.094 >32 >32 >32 
MERa >32 0.38 0.5 0.25 >32 >32 >32 
PIP 512 32 64 32 512 256 1024 
AMP 512 32 512 512 512 1024 1024 
AMP+SUL 32 8 64 64 32 64 64 
CHL 512 128 128 128 526 128 256 
TIG 2 0.12 2 2 0.5 1 2 
TET >1024 4 16 8 >1024 1024 >1024 
ERY 512 8 16 8 512 512 1024 
COL 2 8 1 2 2 4 2 
TMP >1024 16 8 32 32 128 128 
ETBR 512 512 256 256 512 512 256 
CCCP 256 256 256 128 256 256 256 
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PAβN 1024 1024 1024 512 1024 1024 1024 
VER >1024 >1024 >1024 >1024 >1024 >1024 >1024 
H33342 512 512 256 256 256 256 512 
NAL, nalidixic acid; CIP, ciprofloxacin; KAN, kanamycin; GEN, gentamicin; TAZ, 
ceftazidime; TIG, tigecycline; IMP, imipenem; MER, meropenem; PIP, piperacillin, 
AMP, ampicillin; AMP+SUL, ampicillin + sulbactam; CHL, chlorampenicol; TET, 
tetracycline; ERY, erythromycin; COL, colistin; TMP, trimethoprim; VER, verapamil. a 
, MIC values determined by E-test. Resistant values are shown in bold (as per BSAC 





Figure 3.3. Optical density of S3 at 2 hours after growth in the presence of sub-
inhibitory concentrations of CCCP and PAβN. 
 
Data are displayed as a representative example of at least three experiments. The 




reproducible fluorescence (Figure 3.4). Heat-killed cells, which rapidly accumulate 
H33342, were included as a maximum fluorescence level control.  
A H33342 accumulation assay with 2.5 µM H33342 and with cultures at an OD 600 
nm of 0.5 was able to detect different levels of accumulation in the isolates. When 
data were compared with those for AYE differing levels of accumulation were seen 
for the clinical isolates S1- 3 and R1-2 (Figure 3.5). S1, S3, R1 and R2 showed 
significantly higher levels of accumulation of H33342 than AYE. Isolate S2 
accumulated significantly lower levels of H33342 when compared with AYE. There 
was no significant difference in the level of H33342 accumulated in strain AYE and 
clinical isolate R3. 
To assess the ability of CCCP and PAβN to inhibit pumps that efflux H33342, the 
H33342 accumulation assay was carried out in the presence of these EIs. CCCP is 
an uncoupler that can penetrate the membrane and disrupt the proton gradient 
(Lomovskaya and Watkins 2001). It therefore inhibits all efflux pumps that use the 
proton gradient, for example MFS, SMR and RND pumps. PAβN specifically blocks 
RND efflux pumps (Lomovskaya, Warren et al. 2001; Pagès, Masi et al. 2005). 
Addition of CCCP caused a significant increase (p = ≤0.05) in accumulation of 
H33342 in AYE and all clinical isolates tested with fold changes of 1.42 or higher 
(Figure 3.6). S2 and R3 showed the most marked increase in the presence of CCCP, 
with a fold change of 2.00 and 2.15 respectively. Addition of PAβN also significantly 
increased accumulation (p = ≤ 0.05) in all clinical isolates tested (Figure 3.7). The 
highest increase was seen in S3, with a fold change of 1.89. 
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Figure 3.4. Accumulation of 1400µg/ml H33342 in cell cultures of differing 
starting OD600 
 
A, starting OD = 0.1 
B, starting OD = 0.2 
C, starting OD = 0.3 






Figure 3.5 Steady state levels of accumulation of H33342 by strain AYE and 
clinical isolates S1, S2, S3, R1, R2 and R3 at 117 minutes exposure. 
 
Data are displayed as a representative example of at least three separate 
experiments. The standard deviation represents variation between three biological 
replicates. Significant differences in values of the clinical isolates with those for AYE 







Figure 3.6 Fold difference in levels of H33342 accumulated by AYE and clinical 
isolates S1, S2, S3, R1, R2, and R3 at steady state +/- CCCP 
 
Data are displayed as a representative example of at least 3 separate experiments. 
The standard deviation represents variation between three biological replicates. 
Significant differences in values in the presence of CCCP with those without CCCP 







Figure 3.7 Fold difference in levels of H33342 accumulated by AYE and clinical 
isolates S1, S2, S3, R1, R2, and R3 at steady state +/- PAβN 
 
Data are displayed as a representative example of at least 3 separate experiments. 
The standard deviation represents variation between three biological replicates. 
Significant differences in values in the presence of PAβN with those without PAβN 







3.3.3. Accumulation of H33342 by an adeB pump deletion mutant 
The ability of the H33342 accumulation assay to discriminate between pump deletion 
mutants and their parental strains was assessed using MDR strain AB211 and 
AB211ΔadeB. AB211ΔadeB has a deletion in the adeB gene, which encodes the 
inner membrane component of the AdeABC RND efflux pump. Previous studies 
showed that this efflux pump deletion mutant had reduced levels of resistance to 
tigecycline compared with the parental strain (Hornsey, Loman et al. 2011). 
AB211ΔadeB reached steady state accumulation level more rapidly (~32 min) than 
AB211 (~80 min) (Figure 3.8). Steady state levels of dye accumulation at 117 min 
were also significantly higher in the mutant (fluorescence = 1747) when compared 
with the parental strain (fluorescence = 1549), suggesting a reduced level of efflux. 
 
3.3.4. Measurement of H33342 in specific efflux pump deletion mutants 
constructed for this project 
3.3.4.1. Verification of gene deletions and phenotype of pump deletion mutants 
Pump deletion mutants S1ΔadeAB, R2ΔadeFGH, R2ΔadeIJK, R2ΔadeFGHadeIJK 
and R2ΔadeFGHΔP7 were constructed in the laboratory of collaborator Professor 
Kim Lee Chua as part of the MRC-A* funded research project. ‘Pump 7’ (P7) is a 
putative RND family drug transporter identified in ATCC 17978. All mutants were 
checked for deletion of the correct genes using 4 individual PCRs (Table 2.4, PCR 
numbers 2,3,4 and 5) (Primer positions shown in Appendix 2,3,4 and 5). Parental 
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Figure 3.8. Accumulation of H33342 in AB211 and pump deletion mutant 
AB211ΔadeB 
 





strains S1 and R2 were included as negative controls. Mutants were constructed in 
S1 and R2 because these strains were selected as representative of susceptible and 
resistant clinical isolates causing infection in Singaporean hospitals.  Each mutant 
produced an amplimer of the size predicted for the mutation present (Figure 3.9 and 
Table 3.4)). 
Comparison of the growth kinetics of each pump deletion mutant with the parental 
strain showed a reduction in the OD 600 nm at onset of stationary phase in 
S1ΔadeAB, R2ΔadeIJK, R2ΔadeFGHadeIJK and R2ΔadeFGHΔP7 (Figure 3.10 and 
Table 3.5). OD 600 nm was significantly lower (p = ≤0.05) in S1ΔadeAB and 
R2ΔadeFGHΔP7 compared with the parental strain, whereas R2ΔadeIJK and 
R2ΔadeFGHadeIJK had a higher OD 600 nm compared with the parental strain. The 
generation times of S1ΔadeAB, R2ΔadeFGH, R2ΔadeFGHadeIJK and 
R2ΔadeFGHΔP7 were all significantly increased (p = ≤0.05) compared with the 
parental strain. 
Deletion of adeB in Singaporean clinical isolate S1 had no effect on susceptibility to 
the antibiotics tested (Table 3.6). Deletion of adeFGH in Singaporean clinical isolate 
R2 resulted in a one dilution reduction in the MIC of tetracycline (Table 3.7). Deletion 
of this pump also reduced MICs of EIs CCCP and PAβN. Deletion of adeIJK in R2 
conferred increased susceptibility to nalidixic acid, norfloxacin, chloramphenicol, 
tetracycline, tigecycline, trimethoprim, ethidium bromide, CCCP, PAβN and 
verapamil. The mutant R2 in which both adeFGH and adeIJK were deleted had the 
same susceptibility to antibiotics as the mutant in which adeIJK had been deleted.  
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Figure 3.9. and Table 3.4. Verification of gene deletions in pump deletion 
mutants (Table 2.4, PCR numbers 2,3,4 and 5). 
 





1 adeABC check AB211 4100 4100 
2 adeABC check AB211ΔadeB 0 0 
3 adeABC check S1 4100 4100 
4 adeABC check S1ΔadeB 1800 1800 
5 adeABC check Negative control 0 0 
6 adeFGH check R2 7416 7416 
7 adeFGH check R2ΔadeFGH 2000 2000 
8 adeFGH check R2ΔadeFGHΔadeIJK 2000 2000 
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9 adeFGH check R2ΔadeFGHΔP7 2000 2000 
10 adeFGH check Negative control 0 0 
11 adeIJK check R2 3655 3655 
12 adeIJK check R2ΔadeIJK 264 264 
13 adeIJK check R2ΔadeFGHΔadeIJK 264 264 
14 adeIJK check Negative control 0 0 
15 P7 check R2 3328 3328 
16 P7 check R2ΔadeFGHΔP7 2373 2373 





Figure 3.10. Growth kinetics of pump deletion mutants at 37°C as determined 
by optical density. 
 
Table 3.5. Generation times and optical density at onset of stationary phase 
(540 min) 
Strain Generation Time 
(min) 
OD 600 nm at onset of 
stationary phase (540 min) 
AYE 78 0.99 
S1 64 1.06 
S1ΔadeAB 100 0.94 
R2 89 1.00 
R2ΔadeFGH 117 0.98 
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R2ΔadeIJK 91 1.06 
R2ΔadeFGHΔadeIJK 106 1.04 
R2ΔadeFGHΔP7 106 0.95 
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Table 3.6. MIC values of clinically relevant antibiotics for A. baumannii (µg/ml). 
Strain S1 S1ΔadeB 
NAL 8 8 
CIP 0.5 0.5 
NOR 4 4 
KAN 1 1 
GEN 1 1 
TAZ >1024 >1024 
IMPa 0.094 0.094 
MERa 0.38 0.38 
PIP 32 32 
AMP 32 32 
AMP+SUL 8 8 
CHL 128 128 
TIG 0.12 0.12 
TET 4 4 
ERY 8 8 
COL 8 8 
TMP 16 16 
ETBR 512 512 
CCCP 256 256 
PAβN 1024 1024 
 73 
 
VER >1024 >1024 
H33342 512 512 
NAL, nalidixic acid; CIP, ciprofloxacin; KAN, kanamycin; GEN, gentamicin; TAZ, 
ceftazidime; TIG, tigecycline; IMP, imipenem; MER, meropenem; PIP, piperacillin, 
AMP, ampicillin; AMP+SUL, ampicillin + sulbactam; CHL, chlorampenicol; TET, 
tetracycline; ERY, erythromycin; COL, colistin; TMP, trimethoprim; VER, verapamil. a 
, MIC values determined by E-test. Resistant values are shown in bold (as per BSAC 





Table 3.7. MIC values of clinically relevant antibiotics for A. baumannii (µg/ml). 





NAL >1024 >1024 256 256 >1024 
CIP 256 256 256 256 256 
NOR 128 128 64 64 128 
KAN >1024 >1024 >1024 >1024 >1024 
GEN >1024 >1024 >1024 >1024 >1024 
TAZ >1024 >1024 >1024 >1024 >1024 
IMPa >32 >32 >32 >32 >32 
MERa >32 >32 >32 >32 >32 
PIP 256 256 256 256 256 
AMP 1024 1024 1024 1024 1024 
AMP+SUL 64 64 64 64 64 
CHL 128 128 64 64 128 
TIG 1 1 0.25 0.25 1 
TET 1024 512 128 128 512 
ERY 512 512 512 512 512 
COL 4 4 4 4 4 
TMP 128 128 16 16 128 
ETBR 512 512 256 256 512 
CCCP 256 32 8 8 32 
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PAβN 1024 512 512 512 512 
VER >1024 >1024 1024 1024 >1024 
H33342 256 256 256 256 256 
NAL, nalidixic acid; CIP, ciprofloxacin; KAN, kanamycin; GEN, gentamicin; TAZ, 
ceftazidime; TIG, tigecycline; IMP, imipenem; MER, meropenem; PIP, piperacillin, 
AMP, ampicillin; AMP+SUL, ampicillin + sulbactam; CHL, chlorampenicol; TET, 
tetracycline; ERY, erythromycin; COL, colistin; TMP, trimethoprim; VER, verapamil. a 
, MIC values determined by E-test. Resistant values are shown in bold (as per BSAC 













There was a small reduction in the MICs of tetracycline, CCCP and PAβN in 
R2ΔadeFGHΔP7, but these changes were no different to those seen with the single 
deletion of adeFGH and so this mutant was not used in further experiments. 
3.3.4.2. Accumulation of H33342 by efflux pump deletion mutants 
Accumulation of H33342 over time was studied in susceptible clinical isolate S1, 
S1ΔadeB, and three efflux pump deletion mutants from MDR clinical isolate R2, 
R2ΔadeFGH, R2ΔadeIJK, R2ΔadeFGHΔadeIJK. Steady state levels of accumulation 
were taken as a measure of the level of efflux in individual strains. Strains with higher 
levels of steady state accumulation also displayed a higher rate of accumulation and 
reached steady state more rapidly. 
Compared with the parental strain, there was no change in the level of H33342 
accumulated at steady state in S1ΔadeB (Figure 3.11). Addition of CCCP caused a 
significant increase in the level of H33342 accumulated at steady state in both S1 
and S1ΔadeB, with no significant difference between the parent and mutant.  
Compared with the parental strain, when adeFGH was deleted in isolate R2, there 
was a significant 0.69 fold change in the level of H33342 accumulated (Figure 3.12). 
Accumulation was significantly increased in R2ΔadeIJK and R2ΔadeFGHΔadeIJK 
compared with the parental strain, with a fold change of 1.18 and 1.16, respectively.  
Addition of CCCP caused a significant increase in the level of H33342 accumulated 
at steady state (Figure 3.13). This increase was most pronounced in R2ΔadeFGH, 
with a 1.45 fold increase observed. The clinical isolate, R2, showed a smaller 1.31  
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Figure 3.11. Fluorescence of H33342 accumulated by S1 and pump deletion 
mutant +/- CCCP at steady state. 
 
Data are displayed as a representative example of at least 3 separate experiments. 
The standard deviation represents variation between three biological replicates. 
Significant differences in values in the presence of CCCP with those without CCCP 







Figure 3.12. Fold difference in levels of H33342 accumulated by R2 and pump 
deletion mutants at steady state. 
 
Data are displayed as a representative example of at least 3 separate experiments. 
The standard deviation represents variation between three biological replicates. 
Significant differences in values of pump deletion mutants with those for the parental 
strain are indicated with a *, which indicates values returning a p value of ≤0.05 from 






Figure 3.13. Fold difference in levels of H33342 accumulated by R2 and pump 
deletion mutants at steady state +/- CCCP 
 
Data are displayed as a representative example of at least 3 separate experiments. 
The standard deviation represents variation between three biological replicates. 
Significant differences in values in the presence of CCCP with those without CCCP 






fold increase. R2ΔadeIJK and R2ΔadeFGHΔadeIJK showed the smallest fold 
changes of 1.09 and 1.10 respectively. 
Addition of PAβN also caused a significant increase in accumulation of H33342 in all 
strains (Figure 3.14). This increase was greatest in R2ΔadeFGH, with a 1.47 fold 
increase observed. Increase in H33342 accumulation was lower in the parental strain 
R2 and in R2ΔadeIJK and R2ΔadeFGHΔadeIJK mutants with respective fold 
changes of 1.12, 1.19 and 1.24. 
 
3.4. Accumulation of ethidium bromide 
To compare with data obtained with H33342, accumulation of ethidium bromide was 
measured in strain AYE, clinical isolates and pump deletion mutants. Ethidium 
bromide is an alternative dye to H33342 and may be a substrate for different efflux 
pumps. 
 
3.4.1. Accumulation of ethidium bromide in clinical isolates and strain AYE 
Singaporean clinical isolates S1-3 and R1-3 all showed a significant difference in 
accumulation of ethidium bromide compared with reference strain AYE (Figure 3.15). 
R1 and R2 accumulated less than the three antibiotic susceptible isolates. Isolates 
R3 and AYE accumulated more ethidium bromide than R1 and R2, similar to that 
seen for isolates S1-S3. 
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Figure 3.14. Fold difference in levels of H33342 accumulated by R2 and pump 
deletion mutants at steady state.+/- PAβN 
 
Data are displayed as a representative example of at least 3 separate experiments. 
The standard deviation represents variation between three biological replicates. 
Significant differences in values in the presence of PAβN with those without PAβN 







Figure 3.15. Steady state levels of accumulation of ethidium bromide by strain 
AYE and clinical isolates S1, S2, S3, R1, R2 and R3 at 117 minutes exposure 
 
Data are displayed as a representative example of at least three separate 
experiments. The standard deviation represents variation between three biological 
replicates. Significant differences in values of the clinical isolates with those for AYE 





Addition of CCCP caused a significant increase (p = ≤ 0.05) in the level of ethidium 
bromide accumulated at steady state for isolates AYE, R1 and R2 with a 1.54, 1.60 
and 2.59 fold increase, respectively (Figure 3.16). Addition of CCCP had a smaller 
effect on the level of ethidium bromide accumulated in S1 and S3 with a 1.10 and 
1.04 fold increase observed. CCCP had no effect on the level of ethidium bromide 
accumulated in S2 and R3.  
Addition of PAβN also significantly increased (p = ≤0.05) the level of ethidium 
bromide accumulated in AYE, R1 and R2, with a 1.9 fold increase in strain AYE and 
a 1.4 fold increase in both R1 and R2 (Figure 3.17). PAβN had no effect on 
accumulation of ethidium bromide by isolates S1, S2, S3 and R3. 
 
3.4.2. Accumulation of ethidium bromide by efflux pump deletion mutants 
To compare with data obtained with H33342, accumulation of ethidium bromide was 
also studied in efflux pump deletion mutants from MDR clinical isolate R2, 
R2ΔadeFGH, R2ΔadeIJK and R2ΔadeFGHΔadeIJK. As found with H33342, 
R2ΔadeFGH accumulated significantly less ethidium bromide than R2, with a 0.81 
fold change (Figure 3.18). R2ΔadeIJK and R2ΔadeFGHΔadeIJK accumulated 1.85 
and 1.93 fold more ethidium bromide than R2 (p = ≤0.05). 
Addition of CCCP significantly increased levels of ethidium bromide accumulated in 
all strains at steady state (Figure 3.19). The highest increase was seen in 
R2ΔadeFGH with a 2.60 fold change. Addition of CCCP produced a 2.07 fold change  
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Figure 3.16. Fold difference in levels of ethidium bromide accumulated by AYE 
and clinical isolates S1, S2, S3, R1, R2, and R3 at steady state +/- CCCP 
 
Data are displayed as a representative example of at least 3 separate experiments. 
The standard deviation represents variation between three biological replicates. 
Significant differences in values in the presence of CCCP with those without CCCP 






Figure 3.17. Fold difference in levels of ethidium bromide accumulated by AYE 
and clinical isolates S1, S2, S3, R1, R2, and R3 at steady state +/- PAβN 
 
Data are displayed as a representative example of at least 3 separate experiments. 
The standard deviation represents variation between three biological replicates. 
Significant differences in values in the presence of PAβN with those without PAβN 





Figure 3.18. Fold difference in levels of ethidium bromide accumulated by R2 
and pump deletion mutants at steady state 
 
Data are displayed as a representative example of at least 3 separate experiments. 
The standard deviation represents variation between three biological replicates. 
Significant differences in values of pump deletion mutants with those for the parental 
strain are indicated with a *, which indicates values returning a p value of ≤0.05 from 






Figure 3.19. Fold difference in levels of ethidium bromide accumulated by R2 
and pump deletion mutants at steady state +/- CCCP 
 
Data are displayed as a representative example of at least 3 separate experiments. 
The standard deviation represents variation between three biological replicates. 
Significant differences in values in the presence of CCCP with those without CCCP 







in the level of ethidium bromide accumulated in the parental strain, R2, and  
increases of 1.15 and 1.07 fold in mutants R2ΔadeIJK and R2ΔadeFGHΔadeIJK. 
This replicated the pattern seen with addition of CCCP in the H33342 accumulation 
assay. 
Addition of PAβN also increased the level of ethidium bromide accumulated by 1.52 
fold in R2 (Figure 3.20). Addition of PAβN increased the level of ethidium bromide 
accumulated by R2ΔadeFGH, with a 1.93 fold change. Modest increases of 1.13 and 
1.21 fold were seen for mutants R2ΔadeIJK and R2ΔadeFGHΔadeIJK, respectively. 
 
3.5. Uptake of norfloxacin by efflux pump deletion mutants 
To determine whether deletion of adeFGH and adeIJK affected the concentration of 
fluoroquinolone antibiotic accumulated, and whether data for H33342 and/or ethidium 
bromide was similar, norfloxacin accumulation was determined. Norfloxacin is a 
fluoroquinolone antibiotic which exhibits natural fluorescence. Fluoroquinolones have 
been shown to be substrates of RND pumps AdeABC, AdeFGH and AdeIJK (Coyne, 
Courvalin et al. 2011).  
The pattern observed mirrored that seen in H33342 and ethidium bromide 
accumulation assays (3.21). As found with H33342, R2ΔadeFGH accumulated 0.82 
fold less norfloxacin than R2, (Figure 3.21). R2ΔadeIJK and R2ΔadeFGHΔadeIJK 
both accumulated 1.39 fold more norfloxacin than R2. However, none of these 
changes were significant due to the large error between assays.  
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Figure 3.20. Fold difference in levels of ethidium bromide accumulated by R2 
and pump deletion mutants at steady state +/- PAβN 
 
Data are displayed as a representative example of at least 3 separate experiments. 
The standard deviation represents variation between three biological replicates. 
Significant differences in values in the presence of PAβN with those without PAβN 





Figure 3.21. Fold difference in levels of norfloxacin accumulated by R2 and 
pump deletion mutants at steady state 
 
Data are displayed as the mean of 3 separate experiments with a single biological 
replicate. The standard deviation represents variation between three separate 
experiments. Significant differences in values of pump deletion mutants with those for 
the parental strain are indicated with a *, which indicates values returning a p value of 






Addition of CCCP increased the level of norfloxacin accumulated in clinical isolate R2 
by 1.31 fold (Figure 3.22). PAβN had no significant effect on the level of norfloxacin 
accumulated in any strains (Figure 3.23). 
 
3.6. Comparison of data obtained with H33342 with that for ethidium bromide 
and norfloxacin 
Levels of H33342 accumulated by strain AYE and Singaporean clinical isolates were 
different to levels of ethidium bromide accumulated (Table 3.8). Of the clinical 
isolates, S1, S3 and R2 accumulated the most H33342, whereas S2, S3 and R3 
accumulated the most ethidium bromide. Addition of EIs had a different effect on the 
accumulation of H33342 and ethidium bromide. Addition of CCCP significantly 
increased the levels of H33342 accumulated by S2, S3 and R3. However, addition of 
CCCP had no effect on the levels of ethidium bromide accumulated by these 
isolates. Similarly, PAβN increased the levels of H33342 accumulated by S1, S2, S3 
and R3, but had no effect on ethidium bromide accumulation. 
Levels of H44432 accumulated by efflux pump deletion mutants were similar to levels 
of ethidium bromide and norfloxacin accumulated (Table 3.9). There was a significant 
decrease in steady state levels of both H33342 and ethidium bromide accumulated in 
R2ΔadeFGH. There was an increase in steady state levels of both H33342 and 
ethidium bromide accumulated in R2ΔadeIJK and R2ΔadeFGHΔadeIJK.Addition of 
EIs also produced the same affect on accumulation of H33342 and ethidium bromide, 
with the highest increase in accumulation in R2 and R2ΔadeFGH. Measurement of 
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Figure 3.22. Fold difference in levels of norfloxacin accumulated by R2 and 
pump deletion mutants at steady state +/- CCCP  
 
Data are displayed as the mean of 3 separate experiments with a single biological 
replicate. The standard deviation represents variation between three separate 
experiments. Significant differences in values in the presence of CCCP with those 
without CCCP are indicated with a *, which indicates values returning a p value of 






Figure 3.23. Fold difference in levels of norfloxacin accumulated by R2 and 
pump deletion mutants at steady state +/- PAβN  
 
Data are displayed as the mean of 3 separate experiments with a single biological 
replicate. The standard deviation represents variation between three separate 
experiments. Significant differences in values in the presence of PAβN with those 
without PAβN are indicated with a *, which indicates values returning a p value of 






Table 3.8. Fold change in level of H33342, ethidium bromide and norfloxacin 
accumulated in strain AYE and clinical isolates 
  AYE S1 S2 S3 R1 R2 R3 
H33342 Fold change 
compared to 
AYE 
1 1.30 0.83 1.28 1.18 1.23 0.99 
Fold change 
with CCCP 
1.80 1.42 2.15 1.74 1.50 1.52 2.00 
Fold change 
with PAβN 






1 1.08 1.42 1.37 0.86 0.56 1.38 
Fold change 
with CCCP 
1.54 1.11 1.01 1.04 1.60 2.59 0.91 
Fold change 
with PAβN 





Table 3.9. Fold change in level of H33342, ethidium bromide and norfloxacin 
accumulated in efflux pump deletion mutants 












1 1.29 1 0.69 1.19 1.16 
Fold change 
with CCCP 
2.36 1.97 1.31 1.46 1.09 1.10 
Fold change 
with PAβN 







N/A N/A 1 0.81 1.85 1.93 
Fold change 
with CCCP 
N/A N/A 2.08 2.60 1.15 1.07 
Fold change 
with PAβN 









 N/A 1 0.82 1.39 1.39 
Fold change 
with CCCP 
 N/A 1.31 1.38 1.06 1.33 
Fold change 
with PAβN 



































Chapter 4. Discussion 
Increased efflux as a result of over-expression of efflux pumps is a common 
mechanism of MDR in A. baumannii and resistance to a wide range of antibiotics can 
arise from a single mutation in regulatory genes such as adeS (Marchand, Damier-
Piolle et al. 2004). An increase in the MIC of more than one class of antibiotics is 
often assumed to be the result of over-expression of efflux pumps, but levels of efflux 
are not usually measured. 
H33342 displays low toxicity and low mutagenicity when used at a concentration of 
10 µM (Durand and Olive 1982), making it an ideal fluorescent probe for the 
measurement of cellular accumulation. H33342 has previously been used to 
characterise membrane transport activity in mammalian cells (Lalande, Ling et al. 
1981) and Lactococcus lactis (van den Berg van Saparoea, Lubelski et al. 2005), and 
to investigate the contribution of the ABC efflux pump VcaM to MDR in Vibrio 
cholerae and assess efflux activity in E. coli and S. enterica (Huda, Lee et al. 2003). 
Therefore, measurement of the accumulation of Hoechst 33342 could provide a 
sensitive and specific test to quickly and simply measure efflux in A. baumannii. 
In this study, an assay previously developed in this laboratory to measure H33342 
accumulation in Enterobacteriaceae (Coldham, Webber et al. 2010), was adapted for 
use with A. baumannii. Data were compared with that obtained with established 
methods using ethidium bromide and norfloxacin. The suitability of the H33342 
accumulation assay for determining differences in efflux between isolates of A. 
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baumannii was assessed with four MDR clinical isolates and three antibiotic 
susceptible clinical isolates.  
Strain AYE is a previously characterised strain with high resistance to over three 
classes of antibiotic, typical of a MDR strain of A. baumannii. Accumulation of 
H33342 by the cell was seen by the dramatic increase in fluorescence with injection 
of the dye as it entered the cells and bound to DNA and the lipid membrane. Addition 
of CCCP, which dissipates the proton motive force required by a broad range of 
efflux pumps, caused a significant increase in H33342 accumulation, suggesting 
reduced efflux due to the inhibition of active efflux pumps. Addition of PAβN, which 
inhibits RND transporters such as Pseudomonas aeruginosa MexAB (Lomovskaya, 
Warren et al. 2001) and E. coli AcrB (Yu, Aires et al. 2005), also resulted in higher 
levels of H33342 accumulation i.e. reduced level of efflux. However, this reduction 
was not as great as that seen with CCCP, suggesting that although RND pumps 
contribute to efflux in AYE, there are other families of CCCP susceptible efflux pumps 
that also export H33342. 
To allow comparison of efflux levels in Singaporean clinical isolates, the level of 
H33342 accumulated at steady state in each clinical isolate was compared to the 
level accumulated by AYE. The H33342 assay revealed differences in levels of 
accumulation (efflux) between AYE and five of the six clinical isolates tested. Isolate 
S2 accumulated less H33342 than AYE, whilst isolates S1, S3, R1 and R2 
accumulated more H33342 than AYE. This did not correlate well with the MICs of 
antibiotics for these isolates. It was hypothesised that strains exhibiting higher MICs 
of antibiotics would display increased levels of efflux, thus accounting, in part, for 
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their MDR phenotype. However, A. baumannii  has been shown to possess various 
different antibiotic resistance mechanisms (Coyne, Courvalin et al. 2011). Any 
number of these may be present in these clinical isolates and contribute to MDR, 
masking the effect of efflux on the phenotype when measured by MIC. Further 
analysis of the genomes to identify the presence of genes encoding antibiotic 
resistance mechanisms in these isolates is required. 
Addition of CCCP caused a significant decrease in efflux of H33342 in all isolates, 
with the largest effect seen in R3 and S2. These same isolates also accumulated 
less H33342, suggesting a higher level of efflux. In the presence of PAβN, 
accumulation of H33342 was also increased significantly in these two isolates. 
However, the increase was not as large as that seen with CCCP, suggesting that the 
transporters responsible for the higher levels of efflux of H33342 in these isolates are 
not inhibited by PAβN. Efflux in S3 was greatly reduced in the presence of PAβN, 
suggesting that efflux in this isolate may be largely due to RND transporters. This 
demonstrates how studying the effect of specific EIs on the accumulation of H33342 
allows further insight into the classes of efflux pump that contribute to efflux, and 
therefore MDR, in clinical isolates of A. baumannii. 
Comparison of the accumulation of H33342 and ethidium bromide in the clinical 
isolates of A. baumannii revealed different patterns, suggesting that these two 
compounds may be substrates for different pumps. Low levels of accumulation of 
ethidium bromide in isolates R1 and R2 suggest higher levels of efflux and may 
provide an explanation for the MDR phenotype displayed by these isolates. It may be 
that ethidium bromide and antibiotics tested in this study are substrates for the same 
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efflux pumps and so the levels of efflux of ethidium bromide therefore reflect levels of 
antibiotic efflux. In the presence of CCCP, efflux of ethidium bromide was most 
affected in strain AYE and isolates R1 and R2. This was expected as these clinical 
isolates showed the highest level of efflux of this dye. The presence of CCCP gave 
no significant decrease in efflux in isolates R3 and S2, the isolates that showed the 
least ethidium bromide efflux. Interestingly, these two isolates were those that 
showed the highest levels of efflux of H33342 and displayed the largest decrease in 
efflux of this dye with the addition of CCCP (Table 3.7). This suggests that clinical 
isolates of A. baumannii produce efflux pumps with different substrate specificities 
and these may be at different levels. This emphasises the need to use more than one 
substrate to measure efflux when explaining the role of efflux in MDR. Addition of 
PAβN affected efflux of ethidium bromide in a similar way to CCCP. Isolates R1 and 
R2 that effluxed ethidium bromide at high levels also showed the greatest decrease 
in efflux with PAβN. However, the increase was not as high as that seen with CCCP, 
suggesting that although RND transporters contribute to efflux of ethidium bromide in 
these isolates, other families of efflux pumps may also efflux dyes. 
The H33342 accumulation assay was also used to assess whether efflux played a 
role in MDR in Singaporean A. baumannii. Genes encoding efflux pumps previously 
shown to efflux clinically relevant antibiotics in other strains of A. baumannii (Coyne, 
Courvalin et al. 2011) were deleted in clinical isolates S1 and R2 to create pump 
deletion mutants S1ΔadeAB, R2ΔadeFGH, R2ΔadeIJK and R2ΔadeFGHΔadeIJK 
(Kim Lee Chua, manuscript in preparation). H33342 accumulation was also 
measured in AB211 and AB211ΔadeB (Wareham, Gordon et al. 2011). 
 103 
 
The level of H33342 accumulated by AB211ΔadeB was higher than that in the 
parental strain AB211, suggesting that as a result of the lack of AdeB there was 
reduced efflux of this dye in the mutant. Deletion of adeB in susceptible strain, S1, 
had no significant effect on the MICs of the antibiotics tested, or on accumulation of 
H33342, suggesting that the RND pump AdeABC plays no role in resistance to 
antibiotics or efflux of H33342 in this strain. Deletion of adeB has previously been 
shown to reduce MICs of aminoglycosides, β-lactams, fluoroquinolones, 
tetracyclines, tigecycline, macrolides, chloramphenicol and trimethoprim in an MDR 
isolate BM4454 (Magnet, Courvalin et al. 2001). A three-fold increase in ethidium 
bromide accumulation was also observed in this mutant (Magnet, Courvalin et al. 
2001). However, as S1 is susceptible to several antibiotics and over-expression of 
AdeABC is required for MDR (Magnet, Courvalin et al. 2001) it may be that S1 only 
produces low levels of AdeABC and so deletion of adeB has no effect on the 
phenotype.  
Deletion of adeFGH in MDR Singaporean isolate R2 had no effect on MICs of any of 
the antibiotics tested. Whilst over-expression of this system can lead to MDR, Coyne 
et al. have also demonstrated that adeFGH is not expressed in all isolates and 
therefore does not contribute to intrinsic resistance (Coyne, Rosenfeld et al. 2010). A 
triple pump deletion mutant, BM4679 (ΔadeABCΔadeIJKΔadeFGH) displayed the 
same level of resistance as BM4652 (ΔadeABCΔadeIJK), indicating no expression of 
AdeFGH in this strain (Coyne, Rosenfeld et al. 2010). A lack of expression of 
AdeFGH in R2 may explain why deletion of these genes had no effect on resistance. 
However, when compared with the parental strain R2, R2ΔadeFGH did show a 
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significant decrease in accumulation of both H33342 and ethidium bromide, inferring 
increased efflux in the mutant. This may be due to increased expression of another 
efflux system in order to compensate for the loss of AdeFGH. This could also explain 
the lack of change in MIC seen with deletion of adeFGH. Previous work in 
Salmonella enterica serovar Typhimurium has shown that deletion of RND efflux 
pump genes can lead to compensatory altered expression of other efflux pump 
genes. For example, deletion of acrB in SL1344 resulted in a 7.9 fold increase in the 
expression of acrF (Eaves, Ricci et al. 2004). In order to confirm the hypothesis that 
another efflux pump could compensate for loss of adeFGH, transcriptomics are 
necessary to analyse the expression of individual efflux pump genes. Addition of 
CCCP and PAβN also had a greater effect on accumulation of H33342 and ethidium 
bromide in R2ΔadeFGH than in mutants lacking adeIJK, suggesting that efflux 
activity was originally higher in the ΔadeFGH mutant. 
Changes in MICs to particular types of antibiotic tested against R2ΔadeIJK compared 
with the parental strains were similar to changes seen previously in pump deletion 
mutants of strain BM4454 (Damier-Piolle, Magnet et al. 2008; Coyne, Rosenfeld et 
al. 2010). The MICs of antibiotics against the double mutant R2ΔadeFGHΔadeIJK 
were the same as for the single mutant, R2ΔadeIJK and confirmed data obtained 
with the single deletion of adeFGH. Deletion of adeIJK resulted in a significant 
increase in the steady state accumulation levels of both H33342 and ethidium 
bromide. This infers reduced efflux in these mutants, as a consequence of the 
removal of the efflux pump AdeIJK. Addition of both CCCP and PAβN to ΔadeIJK 
and ΔadeFGHadeIJK mutants significantly increased the steady state accumulation 
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levels of H33342 and ethidium bromide, suggesting that, despite lacking AdeIJK, 
these mutants still have efflux activity, presumably as a result of other pump systems. 
However, the increase in accumulation observed in these mutants was not as high as 
that seen with the parental strains and the ΔadeFGH deletion mutant. These data 
suggest that efflux is reduced in strains lacking adeIJK. 
Unlike results seen with clinical isolates, the levels of H33342 and of ethidium 
bromide accumulated at steady state by Singaporean clinical isolate R2 and its efflux 
pump deletion mutants were similar. This confirms that both H33342 and ethidium 
bromide are substrates for the RND pumps deleted in this study and are suitable for 
measuring changes in efflux in these mutants. Although norfloxacin uptake studies 
did not show any significant differences in efflux between the R2 parental strain and 
mutants, perhaps suggesting that this agent is not transported by AdeFGH or 
AdeIJK, each experiment clearly indicated increased accumulation of norfloxacin in 
R2ΔadeIJK and R2ΔadeFGHadeIJK. Coupled with increased susceptibility to 
norfloxacin, it is highly likely that this agent is a substrate for adeIJK. Further work to 
identify the reason for the variability seen in experiments is warranted. 
However, different classes of efflux pumps with different substrate ranges can be 
found in A. baumannii and these may contribute to efflux to varying degrees in 
different isolates. In order to gain a full picture of how efflux affects MDR in clinical 
isolates, it is useful to use more than one dye to measure efflux activity of pumps with 
different substrate ranges. It should also be noted that alterations in outer membrane 
permeability may contribute to changes in dye accumulation. Reduced expression of 
OMPs, such as OmpA, CarO and OmpW, has been seen previously in MDR isolates 
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of A. baumannii (Yun, Choi et al. 2008) and may, at least in part, account for a 
reduced level of accumulation observed in some isolates. 
In summary, the H33342 accumulation assay previously developed for assessment 
of cellular permeability in Enterobacteriaceae has been adapted to provide a cheap, 
rapid and sensitive test for the measurement of efflux in A. baumannii. Measurement 
of the accumulation of H33342 provided a means of characterising MDR strains of A. 
baumannii and assessing the role of efflux in antibiotic resistance. Further 
assessment of the role of efflux in MDR can be investigated with the addition of EIs 
to inhibit different classes of efflux pumps. However, it should be noted that H33342 
may not be a substrate for all efflux pumps present in A. baumannii and use of 
additional compounds such as ethidium bromide may be useful in further 
understanding the levels of efflux in individual isolates. The H33342 assay can also 
be used to assess the contribution of individual efflux pumps by comparing pump 
deletion mutants with their parental strain. Here, accumulation of H33342 has been 
used, with supporting ethidium bromide accumulation data, to show a significant 
difference in the efflux activity of specific pump deletion mutants compared with the 
parental strain. Data obtained in this study support previous work carried out with 
other strains and isolates of A. baumannii and provide an insight into the contribution 




























































The gyrB gene of A. baumannii AYE is shown in capital letters while the upstream 
and downstream flanking regions are shown in lower case. Blue highlighted regions 
indicate primers 1079 and 1081 which produce a 490 bp amplimer in A. baumannii 
and. The red highlighted region indicates primer 1080, which along with 1081 








































































































The genes annotated as adeA  and adeB in A. baumannii ATCC17978 (primer 
design based on this strain) are shown in capital letters while the upstream and 
downstream flanking regions are shown in lower case. Blue highlighted regions 













































































































































The genes annotated as adeF, adeG and adeH in A. baumannii ATCC17978 (primer 
design based on this strain) are shown in capital letters while the upstream and 
downstream flanking regions are shown in lower case. Blue highlighted regions 
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The genes annotated as adeI, adeJ and adeK in A. baumannii ATCC17978 (primer 
design based on this strain) are shown in capital letters while the upstream and 
downstream flanking regions are shown in lower case. Blue highlighted regions 



















































































The genes annotated as A1S_1649 (pump 7)  in A. baumannii ATCC17978 (primer 
design based on this strain) are shown in capital letters while the upstream and 
downstream flanking regions are shown in lower case. Blue highlighted regions 
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